

1 **A Western Dietary Pattern during Pregnancy is Associated with Neurodevelopmental Disorders**
2 **in Childhood and Adolescence**

3 *David Horner MD MSc₁, Jens Richardt M. Jepsen, MSc PhD₂₊₃, Bo Chawes, MD PhD DMSc₁, Kristina*
4 *Aagaard MD₁, Julie B. Rosenberg MD₁₊₂₊₄, Parisa Mohammadzadeh MD₁₊₂₊₄, Astrid Sevelsted MSc*
5 *PhD₁, Nilo Følsgaard MD PhD₁, Rebecca Vinding MD PhD₁, Birgitte Fagerlund PhD₂₊₅, Christos Pantelis*
6 *MBBS MD₆₊₇, Niels Bilenberg MD PhD₈, Casper-Emil T. Pedersen, MSc PhD₁, Anders Eliassen MD,*
7 *PhD₁₊₉, Yulu Chen, PhD₁₀, Nicole Prince, PhD₁₀, Su H. Chu, PhD₁₀, Rachel S. Kelly, PhD₁₀, Jessica*
8 *Lasky-Su, ScD₁₀, Thorhallur I. Halldorsson, PhD₁₁₊₁₂, Marin Strøm, PhD₁₂₊₁₃, Katrine Strandberg-Larsen,*
9 *PhD₁₄, Sjurdur F. Olsen, PhD₁₂₊₁₃₊₁₄₊₁₅, Birte Y. Glenthøj, MD DMSc₂₊₄, Klaus Bønnelykke, MD PhD₁,*
10 *Bjørn H. Ebdrup*, MD PhD₂₊₄, Jakob Stokholm*, MD PhD₁₊₁₆, Morten Arendt Rasmussen*, PhD₁₊₁₆*

11 **These authors contributed equally to this work*

12

13 **Affiliations:**

- 14 1) *COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital,*
15 *University of Copenhagen, Denmark*
- 16 2) *Center for Neuropsychiatric Schizophrenia Research (CNSR) & Centre for Clinical Intervention and*
17 *Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of*
18 *Copenhagen, Glostrup, Denmark*
- 19 3) *Mental Health Centre for Child and Adolescent Psychiatry - Research unit, Mental Health Services in the*
20 *Capital Region of Denmark, Copenhagen, Denmark*
- 21 4) *Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen,*
22 *Copenhagen, Denmark*
- 23 5) *Department of Psychology, University of Copenhagen, Copenhagen, Denmark*
- 24 6) *Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne*
25 *Health, Carlton South, VIC, Australia*
- 26 7) *Florey Institute of Neuroscience & Mental Health, Parkville, VIC, Australia*
- 27 8) *Institute of Clinical Research, University of Southern Denmark, Odense, Denmark*
- 28 9) *Department of Health Technology, Section for Bioinformatics, Technical University of Denmark, Kgs.*
29 *Lyngby, Denmark*

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 30 10) *Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School,*
31 *Boston, MA, USA*
- 32 11) *Faculty of Food Science and Nutrition, School of Health Science, University of Iceland, Health Science*
33 *Institute, Unit for Nutrition Research, Iceland*
- 34 12) *Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark*
- 35 13) *Faculty of Health Sciences, University of the Faroe Islands, Tórshavn, Faroe Islands*
- 36 14) *Section of Epidemiology, Department of Public Health, University of Copenhagen, Denmark*
- 37 15) *Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA*
- 38 16) *Section of Food Microbiology, Gut Health and Fermentation, Department of Food Science, University of*
39 *Copenhagen, Denmark*

40 **ABSTRACT**

41 Despite the high prevalence of neurodevelopmental disorders, there is a notable gap in clinical studies
42 exploring the impact of maternal diet during pregnancy on child neurodevelopment. This observational
43 clinical study examined the association between pregnancy dietary patterns and neurodevelopmental
44 disorders, as well as their symptoms, in a prospective cohort of 10-year-old children (n=508). Data-
45 driven dietary patterns were derived from self-reported food frequency questionnaires. A Western
46 dietary pattern in pregnancy (per SD change) was significantly associated with attention-deficit /
47 hyperactivity disorder (ADHD) (OR 1.66 [1.21 - 2.27], p=0.002) and autism diagnosis (OR 2.22 [1.33 -
48 3.74], p=0.002) and associated symptoms (p<0.001). Findings for ADHD were validated in three large
49 (n=59725, n=656, n=348), independent mother-child cohorts. Objective blood metabolome modelling
50 at 24 weeks gestation identified 15 causally mediating metabolites which significantly improved ADHD
51 prediction in external validation. Temporal analyses across five blood metabolome timepoints in two
52 independent mother-child cohorts revealed that the association of Western dietary pattern metabolite
53 scores with neurodevelopmental outcomes was consistently significant in early to mid-pregnancy,
54 independent of later child timepoints. These findings underscore the importance of early intervention
55 and provide robust evidence for targeted prenatal dietary interventions to prevent neurodevelopmental
56 disorders in children.

57 INTRODUCTION

58 Neurodevelopmental disorders, particularly attention-deficit/hyperactivity disorder (ADHD) and autism,
59 are prevalent and an increasing public health concern (1). In 2020, Danish registers reported a
60 cumulative incidence of 5.9% in males and 3% in females for ADHD, and 4.3% in males and 1.8% in
61 females for autism during childhood and adolescence (2). Large meta-analyses support these findings,
62 with global estimates of 5.9% for ADHD (3) and up to 1.1% for autism (4). In addition,
63 neurodevelopmental disorder symptoms manifest as continuous traits within the paediatric general
64 population (5), and can be reliably captured via validated questionnaires (6,7). Studies have linked
65 several prenatal exposures to neurodevelopmental disorders in children, including maternal obesity,
66 metabolic disturbances, stress, and individual nutritional elements (8). Numerous animal studies have
67 shown that high-fat diets can alter brain morphology (9) and behaviour in offspring in ways resembling
68 neurodevelopmental disorders (10,11), however these findings may not extrapolate well to humans.
69 Dietary constituents may contribute directly to the aforementioned aetiologies, providing both the
70 energy substrates and building blocks for the foetal brain (12). Given the potential public health impact,
71 it is vital to robustly investigate the link between maternal diet during pregnancy and childhood
72 neurodevelopmental disorders, particularly those involving Western diets characterised by high
73 consumption of processed meats, sugars, refined grains, and low intakes of fruits and vegetables.
74 These diets, which are prevalent in modern societies, starkly contrast with historical human diets and
75 may influence developmental outcomes (13). Existing literature lacks objective measurements of
76 dietary patterns in pregnancy, and adjustment for confounding dietary patterns in childhood, when
77 assessing this relationship.

78 The placenta transfers nutrients from the mother to the developing foetus during pregnancy (14). These
79 nutrients, which include the essential n-3 long chain polyunsaturated fatty acids (n3-LCPUFA) and
80 micronutrients such as iron, choline, iodine, zinc, and vitamins B, D, and E, are necessary for foetal
81 brain development and function (12,15), and are obtained as part of a healthy dietary pattern. While the
82 precise mechanisms underlying the influence of maternal diet on offspring neurodevelopment remain
83 to be fully elucidated, various factors may be implicated in developmental processes. Among these
84 factors are the potential impacts of dietary compounds (16) and lipid profiles (17). For example, certain
85 dietary-derived metabolites may interact with developmental pathways in the foetus, potentially

86 affecting neurodevelopmental outcomes (18). Additionally, higher maternal intakes of n3-LCPUFAs,
87 such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are associated with
88 better overall diet quality (19), are reported to be neuroprotective (20).

89 Genetics contribute significantly to neurodevelopmental disorders, with heritability estimates as high as
90 80% (21). The increasing prevalence of these disorders (22) highlight the need for a better
91 understanding of how environmental factors interact with genetic risk (23). In this context, pregnancy
92 dietary influences may be moderated by the child's underlying genetic risk for neurodevelopmental
93 disorders, which can be succinctly captured in a polygenic risk score (PRS) (24). While twin studies
94 consider gene-environment interactions when estimating heritability, clinical evidence validating this
95 potential interaction is notably lacking (25).

96 In this study, we hypothesise that a Western dietary pattern in pregnancy is associated with adverse
97 neurodevelopmental outcomes. We sought to bridge the research gap by leveraging the thorough
98 neurodevelopmental clinical examinations within the Copenhagen Prospective Studies on Asthma in
99 Childhood 2010 (COPSAC2010) mother-child cohort. We employ external validation approaches in
100 three independent mother-child cohorts. Drawing from twelve metabolome datasets from three mother-
101 child cohorts, we juxtapose maternal and child blood profiles to shed light on the temporality of dietary
102 associations and their potential impact on neurodevelopment and delve into which metabolites may be
103 driving dietary associations on neurodevelopment.

104 RESULTS

105 Cohort Characteristics

106 During the 10-year clinical visit, a total of 593 children (84.7%) participating in the COpenhagen
107 Prospective Study on Neuro-PSYCHiatric Development study (COPSYCH) underwent clinical
108 examination for neurodevelopmental and other psychiatric disorders. Additionally, 11 children who did
109 not complete the clinical examination, had information regarding their neurodevelopmental symptom
110 loads. There were no significant differences in baseline sociodemographic characteristics between
111 participants and non-participants at the 10-year visit (*Table S1*), nor between male and female children
112 (*Table S2*).

113 We included 508 children with both pregnancy dietary and clinical data in our analysis, 77 (15.2%, 71%
114 male) had any neurodevelopmental disorder. Specifically, 55 (10.8%, 76% male) were diagnosed with
115 ADHD (25 ADHD predominantly inattentive presentation and 30 ADHD combined presentation) and 13
116 (2.6%, 69% male) with autism.

117 Identification of Dietary Patterns

118 We used principal component analysis (PCA) on 95 nutrient constituents (*Table S3*) from pregnancy
119 food frequency questionnaires (FFQ) assessed at 24 weeks gestation to identify maternal dietary
120 patterns in the COPSAC2010 cohort (*Figure S1*). Principal component 1 (PC1), which explained 44.3%
121 of the variance, had a positive association across all food groups and represents a "Varied dietary
122 pattern". PC2, which explained 10.7% of the variance, had positive associations with intakes of animal
123 fats, refined grains and high-energy drinks, and negative associations with intakes of fruit, fish, and
124 vegetables, representing a "Western dietary pattern" (*Figure 1*). Regarding macronutrient intake, PC2
125 (Western dietary pattern) predominantly reflected a higher intake of fats (*Figure S2A*), specifically
126 saturated fatty acids (*Figure S2B*). Using the maternal PC model, we predicted a child's Western dietary
127 pattern at 10-years, allowing for a consistent comparison of dietary habits ($r=0.22$). A Western dietary
128 pattern during pregnancy was negatively associated with social circumstances and positively
129 associated with maternal pre-pregnancy body mass index (BMI), smoking during pregnancy, antibiotic
130 use during pregnancy and a Western dietary pattern in children at 10-years of age (*Table 1*).

131 **A Western Dietary Pattern during Pregnancy is Associated with Neurodevelopmental Disorders** 132 **and Symptom Loads in Children**

133 A Western dietary pattern during pregnancy (PC2, per SD change) was significantly associated with
134 any neurodevelopmental disorder (OR 1.53 [1.17-2.00], $p=0.002$), ADHD (OR 1.66 [1.21-2.27],
135 $p=0.002$), and autism (OR 2.22 [1.33-3.74], $p=0.002$) (*Table 2*) in multivariate modelling adjusted for
136 pre-pregnancy maternal BMI, social circumstances, child sex, birth weight, gestational age, pregnancy
137 smoking/antibiotic use, pre-eclampsia and a child Western dietary pattern. It was also significantly
138 associated with symptom loads for ADHD (1.73 [0.98-2.49], $p<0.001$) and autism (3.21 [1.69-4.74],
139 $p<0.001$), with consistent associations observed in an earlier assessment of ADHD symptom load at 8
140 years (1.90 [0.42-4.55], $p<0.001$). Moreover, ADHD symptoms at 6 years, assessed using the
141 hyperactivity/inattention scale from the Strengths and Difficulties Questionnaire (SDQ), were also
142 significant (0.50 [0.29-0.70], $p<0.001$). To illustrate the associations between the Western dietary
143 pattern during pregnancy, neurodevelopmental outcomes, and model covariates, we employed
144 Gaussian graphical models (*Figure 2*).

145 Our findings remained significant after further adjustment for maternal genetic risk for ADHD, total
146 maternal energy intake, genomic principal components, intake of prenatal supplements (*Table S4*), and
147 two prenatal nutrition supplementation randomised controlled trials (n3-LCPUFA and high-dose D
148 vitamin) (*Table S5*). Associations of the pregnancy Western dietary pattern were significant for both
149 male (1.42 [1.02-1.99], $p=0.039$) and female children (1.86 [1.15-3.07], $p=0.012$) for any
150 neurodevelopmental disorder diagnosis (*Table S6*). Neurodevelopmental outcomes showed no
151 significant differences related to child sex (p -interaction >0.12). Associations were comparable for both
152 ADHD-predominantly inattentive presentation (OR 1.71 [1.13-2.56], $p=0.009$) and ADHD-combined
153 presentation (OR 1.51 [1.03-2.20], $p=0.033$). In a subanalysis in children without a neurodevelopmental
154 disorder diagnosis ($n=428$), the pregnancy Western dietary pattern association with ADHD symptom
155 load remained significant (0.63 [0.01-1.25], $p=0.048$) (*Table S7*).

156 **Validating our findings for ADHD in the Danish National Birth Cohort**

157 We sought replication of our findings in the Danish National Birth Cohort (DNBC), which had an identical
158 FFQ assessment undertaken at a comparable gestational age, neurodevelopmental diagnoses derived

159 from national registries, and ADHD symptoms from the hyperactivity/inattention scale of the SDQ
160 questionnaire. In our replication analysis including 59,725 mother-child pairs, we observed prevalences
161 of 6.8% for any neurodevelopmental disorder, 4.6% for ADHD diagnosis, and 2.7% for autism diagnosis.
162 We found that the association of the Western dietary pattern in pregnancy, trained in the COPSAC2010
163 cohort, was significantly associated with ADHD diagnosis (OR 1.07 [1.02-1.11], $p=0.002$), but not for
164 any neurodevelopmental disorder diagnosis (OR 1.03 [1.00-1.07], $p=0.087$) or autism diagnosis (OR
165 1.04 [0.98-1.09], $p=0.351$), in multivariable analysis (*Table S8*). Reinforcing our method, we observed
166 PC2 trained within the DNBC cohort was also significantly associated with ADHD diagnosis (OR 1.05
167 [1.01-1.10], $p=0.018$), with a strong correlation between PC2 trained in COPSAC2010 and the DNBC
168 ($r=0.91$). Moreover, ADHD symptoms at 7 years, assessed in a subset of 37,608 children, were also
169 significantly associated with the Western dietary pattern in pregnancy, trained in COPSAC2010 (0.11
170 [0.09-0.13] $p<0.001$), and within the DNBC (0.11 [0.09-0.13] $p<0.001$), in multivariable analysis.

171 **A Blood Metabolomics-Derived Pregnancy Western Dietary Pattern Score Is Associated with** 172 **Neurodevelopmental Disorders in COPSAC2010**

173 We used the blood metabolome from week 24 gestation to objectively measure the pregnancy Western
174 dietary pattern and validate our self-reported FFQ findings. 43.0% of 760 metabolites were significantly
175 associated with the pregnancy Western dietary pattern, with 34.5% surviving false discovery rate
176 ($q<0.05$). In blood metabolome modelling of the pregnancy Western dietary pattern, 43 metabolites
177 emerged as biomarkers (RMSECV=0.87, $R^2CV=0.24$). Loadings for these metabolites can be seen in
178 *Figure 3* and *Table S9*.

179 A Western dietary pattern-metabolite score (WDP-MS) was derived from this model and was associated
180 (per SD change) with any neurodevelopmental disorder diagnosis (OR 1.42 [1.07-1.90], $p=0.017$), and
181 ADHD diagnosis (OR 1.39 [1.00-1.95], $p<0.05$), but not significantly with autism diagnosis (OR 1.09
182 [0.59-2.00], $p=0.781$).

183 To discern whether any of the 43 metabolites acted as biomarkers, or genuine mediators in the
184 association between the Western dietary pattern and neurodevelopmental disorders, we deployed a
185 backward elimination strategy. Our multivariable mediation analysis, found that 15 metabolites (*Figure*
186 *3*, *Table S9*) mediated the association between the Western dietary pattern and any

187 neurodevelopmental disorder diagnosis. The Western dietary pattern had a total effect of 5.5% on any
188 neurodevelopmental disorder diagnosis, of which 80.3% ($p=0.003$) was mediated through the selected
189 15 metabolites. It became evident that a predominant portion of the metabolites acting as mediators
190 were derived from dietary components and lipids. Prominently, plant-based metabolites such as
191 ergothioneine, carotene diol, and tartrate indicate potential protective effects. Conversely, many lipid-
192 associated metabolites, such as medium chain fatty acids like caprate and caprylate, predominantly
193 exhibited positive loadings, underscoring their possible detrimental impact on neurodevelopment.

194 We explored potential time-dependent associations by predicting an additional four WDP-MS using
195 comparable blood metabolome datasets in mothers (one week postpartum) and children (6 months, 18
196 months, and 6 years). In a sensitivity analysis, which compared the five WDP-MS without including
197 other covariates, significant associations were observed solely with the 24 week gestational WDP-MS
198 for any neurodevelopmental disorder diagnosis (OR 1.50 [1.07-2.11], $p=0.020$), ADHD diagnosis (OR
199 1.58 [1.08-2.33], $p=0.020$) and directionally for autism diagnosis (OR 1.74 [0.84-3.57], $p=0.131$). This
200 was the case despite the strong correlations noted between maternal dietary metabolite scores ($r=0.68$,
201 *Table S10*). Findings were consistent for ADHD (1.43 [0.41-2.45], $p=0.006$) and autism symptom loads
202 (2.86 [0.84-4.89], $p=0.006$). We substantiated these temporal associations by employing linear mixed
203 models. Through this approach, we discerned that the initial magnitude of the Western dietary pattern
204 during pregnancy, reflected by the model's intercept, likewise served as a predictor for any
205 neurodevelopmental disorder (OR 1.56 [1.24-1.97], $p<0.001$), ADHD diagnosis (OR 1.63 [1.25-2.12],
206 $p<0.001$) but not autism diagnosis (OR 1.34 [0.813-2.18], $p=0.242$). Additionally, there were likewise
207 significant associations with ADHD (1.69 [0.99-2.40], $p<0.001$) and autism symptom loads (3.65 [2.24-
208 5.06], $p<0.001$).

209 **Western Dietary Pattern-Metabolite Score Predicts ADHD Diagnosis in the VDAART Mother-** 210 **Child Cohort**

211 As our blood metabolome modelling of the Western dietary pattern during pregnancy was associated
212 with ADHD diagnosis and symptom load in COPSAC2010, we sought replication of our findings in the
213 Vitamin D Antenatal Asthma Reduction Trial cohort (VDAART), a large US-based mother-child cohort.
214 We included participants with corresponding pregnancy blood metabolome and ADHD outcome data
215 ($n=656$). Among the children in the VDAART cohort, caregivers reported a diagnosis for ADHD or

216 attention deficit disorder for 18 children (2.7%) by age 6 years and 57 children (8.7%) by age 8 years.
217 Significant cohort characteristic differences were observed between the COPSAC2010 and VDAART
218 cohorts (*Table S11*), encompassing age, income, maternal education, maternal age, gestational age,
219 maternal smoking, race, maternal pre-pregnancy BMI, birthweight, and caesarean section delivery
220 ($p < 0.001$). Supplementary Figures 3 shows the metabolomic variability in the COPSAC2010 and
221 VDAART, illustrating closely matched variances across pregnancy samples.

222 In the VDAART cohort, which includes blood metabolome profiling at two pregnancy timepoints during
223 early (10-18 week) and late gestation (32-38 weeks), we used COPSAC2010 cohort-trained models to
224 predict two WDP-MS to assess their association with ADHD diagnosis. The metabolite scores at both
225 time points were positively associated with intakes of deep-fried foods, processed meats and margarine,
226 and negatively associated with intakes of various vegetables, whole grain foods and fruit in the VDAART
227 cohort, as assessed by independent food frequency questionnaires (*Figure S4*). There was a strong
228 correlation between the VDAART FFQ's principal component 1 and the predicted WDP-MS during early
229 ($r = 0.48$, $p = 1.4 \times 10^{-46}$) and late ($r = 0.46$, $p = 2.3 \times 10^{-42}$) pregnancy, underscoring the WDP-MS validity in
230 predicting dietary patterns across diverse populations.

231 Despite significant differences in cohort characteristics, our blood metabolomics analysis successfully
232 replicated the univariate association between the WDP-MS and ADHD diagnosis at age 6 in both early
233 (OR 2.64 [1.56-4.64], $p < 0.001$) and late pregnancy (OR 1.85 [1.12-3.16], $p = 0.020$), in the VDAART
234 cohort. After adjusting for similar covariates to those used in the COPSAC2010 cohort, a significant
235 association remained between the WDP-MS and ADHD diagnosis in early pregnancy (OR 2.33 [1.26-
236 4.42], $p = 0.008$) but not in late pregnancy (OR 1.67 [0.90-3.20], $p = 0.113$). For further robustness of our
237 findings, we assessed children ever having had a ADHD diagnosis up to age 8. The WDP-MS
238 successfully univariately replicated, albeit with attenuated estimates in early (OR 1.71 [1.28-2.32],
239 $p < 0.001$) and late pregnancy (OR 1.37 [1.04-1.83], $p = 0.030$). Associations remained significant after
240 multivariable adjustment in early pregnancy (OR 1.45 [1.02-2.06], $p = 0.039$) but not late pregnancy (OR
241 1.11 [0.79-1.58], $p = 0.544$).

242 In sensitivity analysis, we independently employed the backward elimination strategy, previously
243 outlined for the COPSAC2010 cohort, on the metabolites overlapping with the VDAART 10-18 weeks
244 and 32-38 weeks time points. In doing so, we identified the mediating metabolites in the association

245 between the Western dietary pattern in COPSAC2010 to ADHD diagnosis (*Figure S5*). Leveraging
246 COPSAC2010's mediating metabolites, we performed a sensitivity analysis to contrast the performance
247 of a WDP-MS using only these potentially causally mediating metabolites against the WDP-MS with all
248 metabolites, for predicting ADHD in the VDAART cohort. At the 10-18 week timepoint, in a multivariable
249 model, the subset of mediating metabolites improved ADHD diagnosis prediction at 6 years (OR 2.85
250 [1.60-5.20], $p < 0.001$), significantly more so (nested model chi-squared test $p = 0.012$) than our model
251 with all 18 metabolites. However, at the 32-38 week timepoint the subset of mediating metabolites (OR
252 1.81 [0.95-3.58], $p = 0.078$) did not perform significantly better than the WDP-MS with all 19 metabolites
253 (nested model chi-squared test $p = 0.423$). To replicate the potential time-dependent association of the
254 Western dietary pattern, we predicted three additional WDP-MS for children in VDAART (1 year, 3
255 years, and 6 years). When incorporating the three child WDP-MS in a model with the two pregnancy
256 WDP-MS timepoints, we observed significant associations only with the early pregnancy WDP-MS for
257 ADHD diagnosis at age 6 (OR 1.97 [1.01-3.80], $p = 0.044$) and ADHD diagnosis up to age 8 (OR 1.65
258 [1.11-2.45], $p = 0.013$).

259 **Western Dietary Pattern-Metabolite Score Predicts ADHD Symptoms in COPSAC2000**

260 We sought further replication in the COPSAC2000 mother-child cohort, where we included 328
261 participants with both neonatal dried blood spots (DBS) metabolic profiling and ADHD symptom load
262 from the Adult ADHD Self-Report Scale (ASRS) at age 18. We developed a Western dietary pattern dry
263 blood spot (WDP-DBS) score using overlapping DBS metabolites from the COPSAC2010 cohort to
264 predict the association with ADHD symptom load. Supplementary Figure 6 illustrates the metabolomic
265 variability between the COPSAC2010 and COPSAC2000 newborn samples, demonstrating
266 comparable variance across cohorts.

267 To substantiate the WDP-DBS score's relevance, we first confirmed its significance within the
268 COPSAC2010 cohort, showing a strong association with ADHD symptom load, in multivariable
269 modelling (1.19 [0.41-1.98], $p = 0.003$), before applying it to COPSAC2000 data. In COPSAC2000, we
270 successfully replicated this association between the WDP-DBS and ADHD symptom load (0.44 [0.01-
271 0.86], $p = 0.045$), but this finding didn't survive covariate adjustment (0.34 [-0.08-0.77], $p = 0.114$). In
272 sensitivity analysis, we enhanced cross-correlations between COPSAC2010 and COPSAC2000
273 cohorts from >0.4 to >0.6 , and restricted the analysis to 626 metabolites with similar distributions

274 between cohorts (Kolmogorov-Smirnov $p \geq 0.05$). This approach led to more pronounced univariate
275 (0.49 [0.06-0.91], $p=0.027$) and multivariable associations (0.41 [-0.02-0.83], $p=0.062$).

276 **Moderating Effects of Genetics, Maternal BMI, and Child Sex on Diet-Neurodevelopment** 277 **Associations**

278 In a subanalysis, we investigated if established risk factors (child genetic risk (ADHD and autism PRS),
279 maternal pre-pregnancy BMI, and child sex) moderate the association of the Western dietary pattern
280 during pregnancy with neurodevelopmental outcomes in COPSAC2010. Supplementary Table 12
281 provides more details on the independent associations of these factors on neurodevelopmental
282 outcomes.

283 ADHD (11.8%) and autism (2.7%) diagnosis, had limited variability in our dataset, prompting us to
284 assess the association of the Western dietary pattern using strata of median split maternal pre-
285 pregnancy BMI (above and below 23.7) and PRS scores (*Figure 4A/B*). In multivariable analyses,
286 children born to mothers with a higher BMI and with a greater genetic predisposition for the respective
287 disorder showed the strongest associations with the Western dietary pattern. For ADHD diagnosis, this
288 group had an odds ratio of 2.18 [1.30-3.74], $p=0.004$, and for autism diagnosis, it was 4.59 [2.33-9.78],
289 $p<10^{-4}$. When further stratified by child sex, findings continued to show consistent significance across
290 both sexes (*Figure S7A/B*). Findings were again consistent when considering the objectively measured
291 WDP-MS (*Figure S8A/B*).

292 To assess the association of the Western dietary pattern on ADHD and autism symptom loads, we
293 employed a tertile split. Concordantly, we found that both ADHD and autism consistently showed that
294 the association of the Western dietary pattern was most pronounced in children born to mothers in the
295 highest pre-pregnancy BMI group (>25.4) and in children with the highest genetic risk for the respective
296 disorders (*Figure 4C/D*). For ADHD symptom load, this group had an estimate of 5.07 [3.12-7.03],
297 $p<10^{-6}$, and for autism symptom load it was 13.5 [9.51-17.5], $p<10^{-10}$. When further stratified by child
298 sex, this pronounced association persisted significantly only for male children (ADHD: 8.24 [5.19-11.3],
299 $p<10^{-6}$, autism: 24.6 [19.0-30.2], $p<10^{-4}$) (*Figure S7C/D*). Findings were again consistent when
300 considering the objectively measured WDP-MS (*Figure S8A/B*). A further graphic is provided (*Figure*

301 S9) for ADHD (A-C) and autism symptom loads (D-F) showing model estimates when considering

302 maternal pre-pregnancy BMI across the categories <25, 25-30, and >30.

303

304 **DISCUSSION**

305 In our large prospective general population COPSAC2010 mother-child cohort, we observed strong
306 associations between a Western dietary pattern during pregnancy with ADHD and autism diagnoses,
307 as well as related symptom loads for these disorders in 10-year-old children. Our findings for ADHD
308 were corroborated in three additional cohorts, which together encompass more than 60,000 mother-
309 child pairs. From the 43 metabolites associated with a Western dietary pattern, a subset of 15 mediating
310 metabolites notably strengthened the association with ADHD diagnosis in external validation. In the
311 COPSAC2010 and VDAART cohorts, we consistently found dietary metabolite score associations in
312 early-mid pregnancy had the strongest associations with neurodevelopmental outcomes, suggesting
313 that this may be a particularly sensitive period of neurodevelopment to dietary influences. Finally, we
314 observed that the association of the Western dietary pattern during pregnancy with ADHD and autism
315 diagnoses, as well as symptom loads, was markedly stronger in children with higher genetic
316 predisposition and maternal pre-pregnancy BMI, particularly in male children.

317 Expanding on prior research, our study, reinforced by clinically assessed outcomes, presents
318 compelling evidence indicating a potential association between maternal dietary habits during
319 pregnancy and child neurodevelopment. The persistence of the Western dietary pattern's association
320 on ADHD symptoms, even in children without a neurodevelopmental disorder diagnosis, suggests that
321 the pregnancy Western dietary pattern may also affect the subclinical population. A Norwegian study
322 of 77,768 mother-child pairs found that higher maternal adherence to dietary guidelines was inversely
323 correlated with ADHD diagnosis and symptom severity, while ultra-processed food was positively
324 associated with ADHD symptom severity (26). This study revealed no link between the diet of 3-year-
325 olds and ADHD outcomes, aligning with our results. Conversely, the Raine Study associated a Western
326 dietary pattern in 1,799 adolescents with ADHD but did not explore maternal dietary influences (27). In
327 a cross-cohort study of 800 pregnant women in the US, weak associations were found between
328 established reference dietary patterns and autism-related traits and diagnosis (28). Our study adds to
329 this existing literature by identifying potential temporal associations of a Western dietary pattern on child
330 neurodevelopmental outcomes, using both maternal and child self-reported dietary intakes, and the
331 objective blood metabolome (29).

332 Our findings suggest a potential interplay between the prenatal environment and child genetics that
333 may influence child neurodevelopment. Males with high genetic risk born from mothers with high pre-
334 pregnancy BMI had the strongest associations with the pregnancy Western dietary pattern. Twin studies
335 support the hypothesis that such interactions play a significant role in the development of these
336 disorders (30,31). Whilst heritability for ADHD and autism is high, with genetic influences accounting
337 for approximately 70-80% of the phenotypic variance (32), current estimates for heritability encompass
338 gene-environment interaction effects (33). Our findings highlight the potential significant role of the
339 environment in the aetiology of ADHD and autism. It is worth noting that much of the heritability for
340 ADHD and autism is explained by SNPs in regulatory regions rather than coding regions (34), providing
341 further evidence for the role of the environment in these disorders. This may aid researchers in
342 understanding the underlying mechanisms contributing to the development of these disorders.

343 The main strength of our study is the prospectively assessed COPSAC2010 cohort followed from
344 pregnancy through childhood, with a deep psychiatric and dimensional psychopathological
345 characterization provided by the COPSYCH project. We use pregnancy and early-life samples taken
346 before onset of disease and symptoms, which allows for the identification of potential risk factors and
347 the directionality of associations. The breadth of data from the COPSAC2010 cohort enabled the
348 inclusion of relevant covariates, and the depth of phenotyping allowed for genetic characterisation,
349 making assessments of gene-environment interactions possible. By utilising a validated
350 semiquantitative food frequency questionnaire and identifying dietary patterns via data-driven
351 approaches, our findings more accurately reflect the dietary patterns that are existing in the population
352 (35). We validate this methodology by identifying a highly correlated dietary pattern within the DNBC.
353 Although our analysis lacked information on morning sickness and hyperemesis gravidarum, our FFQ
354 was registered at 24 weeks gestation with 1 month recall, outside the period when these symptoms are
355 commonly experienced. Furthermore, universal accessibility of a uniform prenatal care in Denmark
356 enhances the reliability of our findings. The pregnancy Western dietary pattern was derived from
357 estimates of nutrient constituents, this approach is not novel (36), and is supported by a recent meta-
358 analysis across 123 studies (37), which reported the reliability of FFQs to capture nutrient constituents
359 with correlation coefficients consistently exceeding 0.5 for most nutrients. This nutrient-centric
360 methodology may offer accurate representation of dietary patterns across diverse populations, since
361 nutrients align more closely with biological and physiological processes than food group categories.

362 Acknowledging the limitations of FFQs, including recall bias and quantification challenges, our study
363 incorporates blood metabolomics to provide objective biomarkers for dietary intake. This approach,
364 while not without its own limitations, such as the transient nature of dietary-derived biomarkers, has
365 validated the Western dietary pattern both internally, through a strong metabolomic imprint, and
366 externally, in two independent FFQs in the VDAART cohort. Many studies have likewise found strong
367 dietary signatures in the metabolome, suggesting this may be a promising avenue for personalised
368 nutrition and targeted therapeutic strategies (29).

369 Our findings for ADHD were strengthened by external validation in three independent mother-child
370 cohorts. This validation enhances the reliability and generalisability of our results, despite the presence
371 of notable differences in cohort characteristics. The validation for ADHD diagnosis in the large-scale
372 DNBC cohort, encompassing 59,725 mother-child pairs, underscores the significant relevance and
373 utility of our findings in the general population. Moreover, validation from the US-based VDAART cohort
374 demonstrates the broad applicability of our findings across diverse ethnic and racial groups, dietary
375 habits, and socio-economic spectra. In VDAART, our external validation was significantly strengthened
376 by focusing on a subset of metabolites identified in causal mediation analysis, implying these
377 metabolites may be crucial intermediaries in the associations observed. Additionally, the VDAART
378 findings enhance our understanding from COPSAC2010, with stronger associations of the Western
379 dietary pattern for ADHD in early pregnancy (10-18 weeks), which may reflect a more sensitive period
380 of neurodevelopment. Given this context, it may not be surprising to see weaker associations from
381 neonatal DBS in COPSAC2000, potentially reflecting dietary intakes in late pregnancy.

382 We cannot rule out potential confounding by maternal phenotypic factors that relate to child
383 neurodevelopmental disorders, however supplemental analysis adjusting for maternal genetic risk did
384 not change our main findings. Given the observational nature of our data, we cannot elucidate the
385 critical window of these dietary associations. Moreover, it is possible that there are discrepancies in the
386 metabolomics platforms concerning metabolite detection, annotations, and cross-platform compatibility,
387 which may introduce bias. Nevertheless, the same metabolomics platform was employed for all
388 maternal and child timepoints in the COPSAC2010 and VDAART cohorts (HD4, Metabolon, Inc.), as
389 well as for the DBS metabolomics profiles in both the COPSAC2010 and COPSAC2000 cohorts (38).

390 A further limitation is that metabolite scores for children, derived from modelling on pregnant mothers,

391 may not reflect dietary patterns in childhood. However, correlations between pregnancy and child
392 metabolite scores were consistently ≥ 0.33 in both COPSAC2010 and VDAART. Whilst dietary intakes
393 remain stable across pregnancy trimesters (39), our ability to distinguish potential acute effects of a
394 pregnancy Western dietary pattern or longer-term effects is limited by our reliance on a single FFQ
395 assessment.

396 Moving forward, future research should focus on establishing causality to further elucidate the
397 relationship between Western dietary patterns in pregnancy and neurodevelopmental outcomes. While
398 animal studies have provided valuable insights (40), further clinical investigations are warranted. Our
399 findings underscore the potential for targeted prevention strategies, and conducting randomised
400 controlled trials would be instrumental in establishing causality. Additionally, genetic studies could
401 strengthen causal inference in our observational data (41).

402 In conclusion, a Western dietary pattern in pregnancy was strongly associated with ADHD and autism,
403 and with symptom loads for these disorders. Our findings suggest that early to mid-pregnancy may be
404 a particularly sensitive window during which dietary influences may impact child neurodevelopment.
405 Highlighting specific subgroup effects, our research points towards the potential for tailored dietary
406 guidelines during pregnancy, especially for at-risk populations. Ultimately, our research underscores
407 the importance of developing targeted dietary interventions for pregnant women to potentially mitigate
408 the risk of neurodevelopmental disorders in children.

409 **Acknowledgements**

410 We express our deepest gratitude to the children and families of the COPSAC2010, COPSAC2000 and
411 VDAART cohorts for all their support and commitment. We acknowledge and appreciate the unique
412 efforts of the COPSAC research team. We acknowledge all funding received by COPSAC, listed on
413 www.copsac.com. The Lundbeck Foundation (Grant no R16-A1694 and R269-2017-5); The Ministry of
414 Health (Grant no 903516); Danish Council for Strategic Research (Grant no 0603-00280B) and The
415 Capital Region Research Foundation have provided core support to the COPSAC research centre. This
416 project has received funding from the European Research Council (ERC) under the European Union's
417 Horizon 2020 research and innovation programme (grant agreement No. 946228) (BC). MAR is funded
418 by the Novo Nordisk Foundation (Grant no NNF21OC0068517). CP was supported by an Australian
419 National Health and Medical Research Council (NHMRC) L3 Investigator Grant (1196508) and by a
420 grant from the Lundbeck Foundation (ID: R246-2016-3237). JL-S (R01HL123915, R01HL155742, and
421 R01HL141826) and SHC (K01HL153941) are funded through the National Institute of Heart, Lung, and
422 Blood Institute.

423 The Danish National Birth Cohort was established with a significant grant from the Danish National
424 Research Foundation. Additional support was obtained from the Danish Regional Committees, the
425 Pharmacy Foundation, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the
426 Health Foundation and other minor grants. The DNBC Biobank has been supported by the Novo
427 Nordisk Foundation and the Lundbeck Foundation. Follow-up of mothers and children have been
428 supported by the Danish Medical Research Council (SSVF 0646, 271-08-0839/06-066023, O602-
429 01042B, 0602-02738B), the Lundbeck Foundation (195/04, R100-A9193), The Innovation Fund
430 Denmark 0603-00294B (09-067124), the Nordea Foundation (02-2013-2014), Aarhus Ideas (AU R9-
431 A959-13-S804), University of Copenhagen Strategic Grant (IFSV 2012), and the Danish Council for
432 Independent Research (DFF – 4183-00594 and DFF - 4183-00152).

433 **Authors Contributions:**

434 DH has written the first draft of the manuscript. All co-authors have provided important intellectual input
435 and contributed considerably to the analyses and interpretation of the data. All authors guarantee that
436 the accuracy and integrity of any part of the work have been appropriately investigated and resolved
437 and all have approved the final version of the manuscript. The corresponding author had full access to
438 the data, with the exception of the DNBC cohort, where analysis was run by TH. The corresponding
439 author had final responsibility for the decision to submit for publication.

440 **Competing Interests Statement:**

441 BE is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and
442 Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb,
443 Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S.
444 BYG has been the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and
445 Neuropsychiatric Schizophrenia Research (CINS) (January 2009 – December 2021), which was
446 partially financed by an independent grant from the Lundbeck Foundation based on international review
447 and partially financed by the Mental Health Services in the Capital Region of Denmark, the University
448 of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the
449 Capital Region of Denmark and administered by them. She has no other conflicts to disclose. JL-S is a
450 scientific advisor for Precion Inc and a consultant to Tru Diagnostic, Inc.

451 Remaining authors declare no potential, perceived, or real conflict of interest regarding the content of
452 this manuscript. The funding agencies did not have any role in design and conduct of the study;
453 collection, management, and interpretation of the data; or preparation, review, or approval of the
454 manuscript. No pharmaceutical company was involved in the study.





455 **References (Main Text)**

- 456 1. Bougeard C, Picarel-Blanchot F, Schmid R, Campbell R, Buitelaar J. Prevalence of Autism
457 Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature
458 Review. *Front Psychiatry*. 2021 Oct 27;12:744709.
- 459 2. Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, et al.
460 Incidence Rates and Cumulative Incidences of the Full Spectrum of Diagnosed Mental Disorders
461 in Childhood and Adolescence. *JAMA Psychiatry*. 2020 Feb 1;77(2):155–64.
- 462 3. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic
463 review. *Neurotherapeutics*. 2012 Jul;9(3):490–9.
- 464 4. Talantseva OI, Romanova RS, Shurdova EM, Dolgorukova TA, Sologub PS, Titova OS, et al.
465 The global prevalence of autism spectrum disorder: A three-level meta-analysis. *Front Psychiatry*.
466 2023 Feb 9;14:1071181.
- 467 5. Larsson H, Anckarsater H, Råstam M, Chang Z, Lichtenstein P. Childhood attention-deficit
468 hyperactivity disorder as an extreme of a continuous trait: a quantitative genetic study of 8,500
469 twin pairs. *J Child Psychol Psychiatry*. 2012 Jan;53(1):73–80.
- 470 6. Makransky G, Bilenberg N. Psychometric properties of the parent and teacher ADHD Rating
471 Scale (ADHD-RS): measurement invariance across gender, age, and informant. *Assessment*.
472 2014 Dec;21(6):694–705.
- 473 7. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al. Validation of a
474 brief quantitative measure of autistic traits: comparison of the social responsiveness scale with
475 the autism diagnostic interview-revised. *J Autism Dev Disord*. 2003 Aug;33(4):427–33.
- 476 8. Cortés-Albornoz MC, García-Guáqueta DP, Velez-van-Meerbeke A, Talero-Gutiérrez C. Maternal
477 Nutrition and Neurodevelopment: A Scoping Review. *Nutrients* [Internet]. 2021 Oct 8;13(10).
478 Available from: <http://dx.doi.org/10.3390/nu13103530>
- 479 9. Fernandes DJ, Spring S, Roy AR, Qiu LR, Yee Y, Nieman BJ, et al. Exposure to maternal high-
480 fat diet induces extensive changes in the brain of adult offspring. *Transl Psychiatry*. 2021 Mar
481 2;11(1):149.
- 482 10. Giriko CÁ, Andreoli CA, Mennitti LV, Hosoume LF, Souto TDS, Silva AV da, et al. Delayed
483 physical and neurobehavioral development and increased aggressive and depression-like
484 behaviors in the rat offspring of dams fed a high-fat diet. *Int J Dev Neurosci*. 2013
485 Dec;31(8):731–9.
- 486 11. Mitchell AJ, Khambadkone SG, Dunn G, Bagley J, Tamashiro K, Fair D, et al. Maternal
487 Western-style diet reduces social engagement and increases idiosyncratic behavior in Japanese
488 macaque offspring. *Brain Behav Immun* [Internet]. 2022 Jul 6; Available from:
489 <http://dx.doi.org/10.1016/j.bbi.2022.07.004>
- 490 12. Prado E, Dewey K. Nutrition and Brain Development in Early Life [Internet]. *Prenatal and*
491 *Childhood Nutrition*. 2015. p. 79–126. Available from: <http://dx.doi.org/10.1201/b18040-6>
- 492 13. Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, et al. Origins and
493 evolution of the Western diet: health implications for the 21st century. *Am J Clin Nutr*. 2005
494 Feb;81(2):341–54.
- 495 14. Devarshi PP, Grant RW, Ikonte CJ, Hazels Mitmesser S. Maternal Omega-3 Nutrition, Placental
496 Transfer and Fetal Brain Development in Gestational Diabetes and Preeclampsia. *Nutrients*
497 [Internet]. 2019 May 18;11(5). Available from: <http://dx.doi.org/10.3390/nu11051107>
- 498 15. Taylor MR, Chuang C, Carrasco KD, Nagatomo S, Rucklidge JJ. Dietary and Micronutrient
499 Treatments for Children with Neurodevelopment Disorders [Internet]. Vol. 5, *Current*
500 *Developmental Disorders Reports*. 2018. p. 243–52. Available from:






- 501 <http://dx.doi.org/10.1007/s40474-018-0150-5>
- 502 16. Halliwell B, Cheah IK, Tang RMY. Ergothioneine - a diet-derived antioxidant with therapeutic
503 potential. *FEBS Lett.* 2018 Oct;592(20):3357–66.
- 504 17. Prince N, Chu SH, Chen Y, Mendez KM, Hanson E, Green-Snyder L, et al. Phenotypically driven
505 subgroups of ASD display distinct metabolomic profiles. *Brain Behav Immun.* 2023 Jul;111:21–9.
- 506 18. Poornimai Abirami GP, Radhakrishnan RK, Johnson E, Roshan SA, Yesudhas A, Parveen S, et
507 al. The Regulation of Reactive Neuroblastosis, Neuroplasticity, and Nutraceuticals for Effective
508 Management of Autism Spectrum Disorder. *Adv Neurobiol.* 2020;24:207–22.
- 509 19. Naveed S, Lakka T, Haapala EA. An Overview on the Associations between Health Behaviors
510 and Brain Health in Children and Adolescents with Special Reference to Diet Quality [Internet].
511 Vol. 17, *International Journal of Environmental Research and Public Health.* 2020. p. 953.
512 Available from: <http://dx.doi.org/10.3390/ijerph17030953>
- 513 20. Basak S, Duttaroy AK. Maternal PUFAs, Placental Epigenetics, and Their Relevance to Fetal
514 Growth and Brain Development. *Reprod Sci [Internet].* 2022 Jun 8; Available from:
515 <http://dx.doi.org/10.1007/s43032-022-00989-w>
- 516 21. Pettersson E, Lichtenstein P, Larsson H, Song J, Attention Deficit/Hyperactivity Disorder Working
517 Group of the iPSYCH-Broad-PGC Consortium, Autism Spectrum Disorder Working Group of the
518 iPSYCH-Broad-PGC Consortium, Bipolar Disorder Working Group of the PGC, Eating Disorder
519 Working Group of the PGC, Major Depressive Disorder Working Group of the PGC, Obsessive
520 Compulsive Disorders and Tourette Syndrome Working Group of the PGC, Schizophrenia
521 CLOZUK, Substance Use Disorder Working Group of the PGC, Agrawal A, et al. Genetic
522 influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings,
523 and genetic data of 333 748 cases and controls - CORRIGENDUM. *Psychol Med.* 2019
524 Jan;49(2):351.
- 525 22. Atladottir HO, Gyllenberg D, Langridge A, Sandin S, Hansen SN, Leonard H, et al. The
526 increasing prevalence of reported diagnoses of childhood psychiatric disorders: a descriptive
527 multinational comparison. *Eur Child Adolesc Psychiatry.* 2015 Feb;24(2):173–83.
- 528 23. Tran NQV, Miyake K. Neurodevelopmental Disorders and Environmental Toxicants: Epigenetics
529 as an Underlying Mechanism. *Int J Genomics Proteomics [Internet].* 2017 [cited 2023 Jan
530 7];2017. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439185/>
- 531 24. Keers R, Coleman JRI, Lester KJ, Roberts S, Breen G, Thastum M, et al. A Genome-Wide Test
532 of the Differential Susceptibility Hypothesis Reveals a Genetic Predictor of Differential Response
533 to Psychological Treatments for Child Anxiety Disorders. *Psychother Psychosom.* 2016 Apr
534 5;85(3):146–58.
- 535 25. Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World
536 Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about
537 the disorder. *Neurosci Biobehav Rev.* 2021 Sep;128:789–818.
- 538 26. Borge TC, Biele G, Papadopoulou E, Andersen LF, Jacka F, Eggesbø M, et al. The associations
539 between maternal and child diet quality and child ADHD - findings from a large Norwegian
540 pregnancy cohort study. *BMC Psychiatry.* 2021 Mar 8;21(1):139.
- 541 27. Howard AL, Robinson M, Smith GJ, Ambrosini GL, Piek JP, Oddy WH. ADHD is associated with
542 a “Western” dietary pattern in adolescents. *J Atten Disord.* 2011 Jul;15(5):403–11.
- 543 28. Vecchione R, Wang S, Rando J, Chavarro JE, Croen LA, Fallin MD, et al. Maternal Dietary
544 Patterns during Pregnancy and Child Autism-Related Traits: Results from Two US Cohorts.
545 *Nutrients [Internet].* 2022 Jun 30;14(13). Available from: <http://dx.doi.org/10.3390/nu14132729>
- 546 29. Noerman S, Landberg R. Blood metabolite profiles linking dietary patterns with health-Toward
547 precision nutrition. *J Intern Med.* 2023 Apr;293(4):408–32.

- 548 30. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. *Mol Psychiatry*. 2019
549 Apr;24(4):562–75.
- 550 31. Santos JX, Rasga C, Marques AR, Martiniano H, Asif M, Vilela J, et al. A Role for Gene-
551 Environment Interactions in Autism Spectrum Disorder Is Supported by Variants in Genes
552 Regulating the Effects of Exposure to Xenobiotics. *Front Neurosci*. 2022 May 19;16:862315.
- 553 32. Ma SL, Chen LH, Lee CC, Lai KYC, Hung SF, Tang CP, et al. Genetic Overlap Between
554 Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Gene. *Front Neurosci*.
555 2021 Apr 27;15:649588.
- 556 33. Bateson P, Gluckman P. *Plasticity, Robustness, Development and Evolution*. Cambridge
557 University Press; 2011. 166 p.
- 558 34. Gusev A, Lee SH, Trynka G, Finucane H, Vilhjálmsón BJ, Xu H, et al. Partitioning heritability of
559 regulatory and cell-type-specific variants across 11 common diseases. *Am J Hum Genet*. 2014
560 Nov 6;95(5):535–52.
- 561 35. Newby PK, Tucker KL. Empirically derived eating patterns using factor or cluster analysis: a
562 review. *Nutr Rev*. 2004 May;62(5):177–203.
- 563 36. Zhao J, Li Z, Gao Q, Zhao H, Chen S, Huang L, et al. A review of statistical methods for dietary
564 pattern analysis. *Nutr J*. 2021 Apr 19;20(1):37.
- 565 37. Cui Q, Xia Y, Wu Q, Chang Q, Niu K, Zhao Y. A meta-analysis of the reproducibility of food
566 frequency questionnaires in nutritional epidemiological studies. *Int J Behav Nutr Phys Act*. 2021
567 Jan 11;18(1):12.
- 568 38. Gürdeniz G, Ernst M, Rago D, Kim M, Courraud J, Stokholm J, et al. Neonatal metabolome of
569 caesarean section and risk of childhood asthma. *Eur Respir J [Internet]*. 2022 Jun;59(6).
570 Available from: <http://dx.doi.org/10.1183/13993003.02406-2021>
- 571 39. Savard C, Lemieux S, Weisnagel S, Fontaine-Bisson B, Gagnon C, Robitaille J, et al. Trimester-
572 Specific Dietary Intakes in a Sample of French-Canadian Pregnant Women in Comparison with
573 National Nutritional Guidelines [Internet]. Vol. 10, *Nutrients*. 2018. p. 768. Available from:
574 <http://dx.doi.org/10.3390/nu10060768>
- 575 40. Urbonaite G, Knyzeliene A, Bunn FS, Smalskys A, Neniskyte U. The impact of maternal high-fat
576 diet on offspring neurodevelopment [Internet]. Vol. 16, *Frontiers in Neuroscience*. 2022. Available
577 from: <http://dx.doi.org/10.3389/fnins.2022.909762>
- 578 41. Pingault JB, O'Reilly PF, Schoeler T, Ploubidis GB, Rijdsdijk F, Dudbridge F. Using genetic data to
579 strengthen causal inference in observational research. *Nat Rev Genet*. 2018 Sep;19(9):566–80.

580 **FIGURES**




582 **Figure 1.** Figure showing the pregnancy Varied and Western dietary patterns derived from nutrient
583 constituents (PC1 and PC2) and their associations with food groups. Multivariable analysis shows the
584 Western dietary pattern is highly associated with any neurodevelopmental disorder diagnosis (OR 1.53,
585 [1.17 - 2] ($p = 0.002$), ADHD diagnosis 1.66 [1.21 - 2.27] ($p = 0.002$), and autism diagnosis 2.22 [1.33 -
586 3.74] ($p = 0.002$), but the Varied dietary pattern is not significantly associated with neurodevelopmental
587 disorders ($p > 0.288$). Yellow represents positive associations with PC1, while red and green denote
588 positive and negative associations with PC2, respectively.



590 **Figure 2.** Graphical models illustrate associations (partial correlations $p < 0.05$) between the Western
591 dietary pattern during pregnancy, neurodevelopmental outcomes A: ADHD diagnosis, B: ADHD
592 Symptom Load (ADHD-RS), C: Autism diagnosis, D: Autism Symptom Load (SRS-2), and model
593 covariates. Models include child ADHD PRS (A&B) and autism PRS (C&D) as additional covariates.


Metabolites Reflecting a Western Dietary Pattern and Their Mediation in Neurodevelopmental Disorders



Metabolite Pathway: Amino Acid (teal), Cofactors and Vitamins (yellow), Lipid (purple), Partially Characterized Molecules (red), Xenobiotics (blue). Mediation: Yes (hatched), No (white).

595 **Figure 3.** The 43 metabolites, selected by the sparse partial least squares model, represent those
596 associated with the Western dietary pattern during pregnancy at 24 weeks gestation in COPSAC2010.
597 Positive metabolite scores indicate a positive association, while negative scores suggest an inverse
598 relationship with this dietary pattern. A systematic backward elimination pinpointed 15 metabolites as
599 mediators between the Western dietary pattern and any neurodevelopmental disorders. Notably,
600 dietary-derived compounds, like ergothioneine, suggest potential protective roles, while certain lipid-
601 associated metabolites hint at possible detrimental impacts on neurodevelopment.

Western Dietary Pattern Associations with Neurodevelopmental Disorders



603 **Figure 4.** Modulation of the Western Dietary Pattern on Neurodevelopmental Outcomes in
604 COPSAC2010 Cohort. Odds ratio estimates for ADHD (A) and autism diagnoses (B) based on
605 interactions of the Western dietary pattern, maternal pre-pregnancy BMI (split at median value 23.7),
606 and child's polygenic risk score (PRS) (median split) for ADHD and autism. Estimates for ADHD (C)
607 and autism (D) symptom loads based on the Western dietary pattern, considering tertiles of maternal
608 pre-pregnancy BMI and child's PRS for ADHD and autism. Odds ratios and estimates are in relation to
609 a change of 1 SD of the Western dietary pattern. Stars represent significance levels: * indicates $p <$
610 0.05, ** indicates $p < 0.01$, and *** indicates $p < 0.001$, with "NS" denoting non-significant results ($p \geq$
611 0.05). Further details, including the individual associations of these modulating factors, can be found in
612 Table S11.

613 TABLES

Western Dietary Pattern (PC2) Covariate Associations	Low Western Diet	Mid Western Diet	High Western Diet	p-value
n =	170	169	169	
Male Sex (%)	77 (45.3)	98 (58.0)	91 (53.8)	0.058
Social circumstances (mean (SD))	0.34 (0.87)	0.06 (0.94)	-0.41 (1.01)	<0.001
Maternal pre-pregnancy BMI (mean(SD))	24.12 (4.18)	24.41 (3.80)	25.36 (5.06)	0.026
Smoking during pregnancy (%)	5 (2.9)	7 (4.1)	26 (15.4)	<0.001
Gestational age in (days) (mean (SD))	279.18 (12.36)	279.62 (11.43)	279.14 (10.13)	0.911
Birthweight (kg) (mean (SD))	3.55 (0.56)	3.55 (0.53)	3.58 (0.53)	0.815
Antibiotics during pregnancy (%)	49 (29.0)	53 (31.4)	73 (43.2)	0.013
Pre-eclampsia during pregnancy (%)	5 (3.0)	9 (5.3)	8 (4.7)	0.539
Child Western Dietary Pattern (mean (SD))	-0.18 (0.89)	-0.07 (1.01)	0.26 (1.08)	<0.001
n3-LCPUFA Pregnancy RCT (%)	82 (48.2)	88 (52.1)	88 (52.1)	0.717
High dose Vitamin D Pregnancy RCT (%)	70 (51.1)	66 (47.1)	64 (45.4)	0.622
Total energy consumption (FFQ) (mean (SD))	9131 (1982)	8497 (1968)	9502 (2545)	<0.001
Maternal ADHD PRS (mean (SD))	-0.12 (1.00)	-0.05 (0.97)	0.09 (1.04)	0.208
Child ADHD PRS (mean (SD))	-0.17 (1.06)	-0.03 (1.00)	0.11 (0.99)	0.060
Child Autism PRS (mean (SD))	-0.01 (1.02)	-0.05 (1.05)	-0.01 (1.04)	0.921

614

615 **Table 1.** Model covariates stratified by low, middle and high (tertiles) for the pregnancy Western dietary
 616 pattern, in children who were clinically assessed for neurodevelopmental disorders.

617 **Footnote:**

618 † PC2: Principal Component 2, BMI: Body Mass Index, RCT: Randomised Controlled Trial, FFQ: Food Frequency Questionnaire,

619 PRS: Polygenic Risk Score.

	Univariate Model	Multivariable Model
Neurodevelopmental Diagnosis	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value
Any Neurodevelopmental Disorder Diagnosis	1.66 [1.31 - 2.11] (p < 0.001)	1.53 [1.17 - 2.00] (p = 0.002)
ADHD Diagnosis	1.84 [1.42 - 2.41] (p < 0.001)	1.66 [1.21 - 2.27] (p = 0.002)
Autism Diagnosis	2.38 [1.50 - 3.79] (p < 0.001)	2.22 [1.33 - 3.74] (p = 0.002)
Neurodevelopmental Symptom Loads	Estimate [95% CI] p-value	Estimate [95% CI] p-value
ADHD Symptom Load (ADHD-RS)	2.26 [1.53 - 2.98] (p < 0.001)	1.73 [0.98 - 2.49] (p < 0.001)
Autism Symptom Load (SRS-2)	4.37 [2.92 - 5.81] (p < 0.001)	3.21 [1.69 - 4.74] (p < 0.001)

620

621 **Table 2.** Regression analysis of the Western dietary pattern during pregnancy and neurodevelopmental
622 outcomes. Odds ratios and estimates are interpreted as the association of 1 standard deviation of the
623 pregnancy Western dietary pattern. **Model A:** Univariate analysis. **Model B:** Multivariable analysis
624 (multivariable model adjusted for pre-pregnancy maternal BMI, social circumstances (household
625 income, maternal education level, and maternal age), child sex, birth weight, gestational age, pregnancy
626 smoking/antibiotic use, pre-eclampsia and a child Western dietary pattern at 10-years of age).

627 **METHODS**

628 **Study Design**

629 The primary analysis of our research was conducted within the Copenhagen Prospective Studies on
630 Asthma in Childhood (COPSAC2010) mother-child cohort, supplemented by validation analyses in
631 three independent mother-child cohorts: the Danish National Birth Cohort (DNBC), the Vitamin D
632 Antenatal Asthma Reduction Trial (VDAART), and COPSAC2000. The COPSAC2010 cohort includes
633 700 mother-child pairs with extensive phenotyping from 14 clinical visits and exposure assessments
634 since birth, including infants born within a gestational range of 30 to 42 weeks, thus covering both
635 preterm and full-term births (42). Outcome data for this study was derived from the COpenhagen
636 Prospective Study on Neuro-PSYCHiatric Development (COPSYCH) study (43) nested within the
637 COPSAC2010 mother-child cohort, at age 10 years.

638 In validation analysis, we utilised the DNBC, a large mother-child cohort that recruited over 100,000
639 pregnant mothers from early gestation, approximately 35% of pregnancies during the recruitment
640 period, to validate our findings of the food frequency questionnaire derived dietary pattern (44,45).
641 Furthermore, we used the large independent US-based VDAART mother-child cohort (NCT00920621)
642 ($n=656$) (46), to validate our blood metabolome modelling (47), and further validated our findings in the
643 COPSAC2000 cohort ($n=348$), using metabolic profiles from neonatal dried blood spots (DBS) (48).

644 **The COPSYCH 10-year visit**

645 The COPSYCH study comprised a 2-day clinical visit that focused on neurodevelopment, reflected by
646 neurocognition and psychopathology (43). Clinical examinations were carried out between January
647 2019 and December 2021.

648 We used both the International Classification of Disorders 10th Revision (ICD-10) of Mental and
649 Behavioural Disorders: Clinical descriptions and diagnostic guidelines and Diagnostic and Statistical
650 Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for research diagnoses based on clinical
651 information from the 10-year visit. ADHD ICD-10 diagnostic codes assigned at the COPSYCH visit
652 included: DF90.0 (*Disturbance of activity and attention*), DF90.8 (*Other hyperkinetic disorders*) and
653 DF98.8C (*Attention deficit disorder without hyperactivity*). For secondary analysis, we further specified

654 *ADHD combined presentation* (DSM-5) (fulfilling ICD-10 DF90.0 or DF90.8) and *ADHD predominantly*
655 *inattentive presentation* (DSM-5) (fulfilling ICD-10 DF98.8C). Autism ICD-10 diagnostic codes assigned
656 were: DF84.0 (*Childhood autism*), DF84.5 (*Asperger's syndrome*) and DF84.8 (*Other pervasive*
657 *developmental disorders*). For our analysis, we also included additional neurodevelopmental disorder
658 codes under the umbrella of 'any neurodevelopmental disorder', including DF95.1 (*chronic motor or*
659 *vocal tic disorder*), DF95.2 (*Tourette's syndrome*), DF88 (*Other disorders of psychological*
660 *development*), and DF89 (*Unspecified disorder of psychological development*), in addition to ADHD and
661 autism as previously described.

662 The ADHD Rating Scale (ADHD-RS) questionnaire was completed by parents to assess the severity of
663 inattentive and impulsive-hyperactive symptoms (6), and the Social Responsiveness Scale-2 (SRS-2)
664 was used to assess the severity of autism traits in the whole cohort (7). Symptom loads are derived
665 from the total scores of the ADHD-RS (Q1-Q18) and SRS-2 questionnaires. Subscales for ADHD-RS
666 and SRS-2 are utilised in subanalysis. In addition, at 6 years, we evaluated hyperactivity/inattention
667 problems using the subscale from the Strengths and Difficulties Questionnaire (SDQ), which scores
668 range from 0 to 10 (49,50).

669 The Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and
670 Lifetime Version (K-SADS-PL) (25) was used to assess current and lifetime psychopathology through
671 a general screening interview and supplementary interview for relevant disorders (51). All K-SADS-PL
672 interviews were conducted by a trained clinician. If certain thresholds are reached, a supplementary
673 interview is conducted to assign relevant diagnoses based on all available information. Consensus
674 diagnoses were made between senior researcher and psychologist with specialty in child and
675 adolescent psychiatry (JRMJ) and at least two examiners according to both the Diagnostic and
676 Statistical Manual of Mental Disorders, Fifth Edition (52) and the International Classification of Disorders
677 10th Revision (ICD-10) of Mental and Behavioural Disorders: Clinical descriptions and diagnostic
678 guidelines (53). Diagnostic classification was further validated by a professor in child and adolescent
679 psychiatry (NB). An estimation of interrater reliability on the symptom level was performed based on
680 video recordings of 10 participants with JRJM as the gold standard. The overall agreement, including
681 both currently present and not present symptoms, was 99.48% (95%CI 99.25-99.66). The agreement
682 specifically on present symptoms was 88.48% (95%CI 82.60-92.92).

683 **Food Frequency Questionnaires and Pregnancy Dietary Patterns**

684 At 24 weeks of gestation, upon their recruitment to the COPSAC2010 cohort, mothers were asked to
685 complete a validated semi-quantitative FFQ with a one-month recall period, encompassing 360 items
686 detailing their dietary intake over the previous month. Mothers in COPSAC2010 and DNBC were
687 subsequently excluded from the analysis for reporting unrealistic energy intakes, either below 4,200
688 kJ/day or exceeding 16,700 kJ/day. Utilised in both the DNBC validation cohort and the COPSAC2010
689 cohort, this FFQ has been validated in both a group of younger women (54) and for pregnant women
690 (55,56). The timing of FFQ completion at week 25 in the DNBC cohort, closely aligned with the
691 COPSAC2010 cohort's at 24 weeks, and thus facilitates the examination of dietary pattern associations
692 on neurodevelopmental outcomes (45). Mothers reported their intake of foods with natural units like
693 apples, while for items without natural units, such as lasagne, they indicated frequency of consumption.
694 Nutrient intakes were estimated using standard portion sizes and recipes, with frequency categories
695 converted to daily intake. Intakes of various food items were calculated based on standard portion size
696 assumptions, measured in grams per day. Nutrient constituents were then determined using the
697 National Food Institute's Food Composition Databank, version 7 (57). Nutrient constituents were
698 selected for analysis due to its association with physiological and metabolic functions, which provides
699 a perspective on biological mechanisms applicable across various populations. During the COPSAC
700 clinical assessment at the age of 10, we collected data on the dietary habits of children. The FFQ,
701 encompassing 145 distinct food items, aimed to capture the consistent dietary habits of children. It has
702 been previously validated for use among adolescents aged 12-15 in the DNBC study (58). Intakes of
703 food groups and nutrient components were measured using the same method as the pregnancy
704 questionnaire mentioned above.

705 In COPSAC2010, principal component analysis (PCA) was used to identify maternal dietary patterns
706 based on the calculated estimates of energy, macronutrient, and micronutrient intake in 613 mothers.
707 In the DNBC cohort, dietary pattern validation was achieved using the principal component model
708 originally trained in COPSAC2010 data, ensuring the identification of directly comparable dietary
709 patterns across the two cohorts. To validate our methodology, we also assessed for associations of a
710 comparable dietary pattern trained within the DNBC. In COPSAC2010, the derived dietary patterns

711 were associated with estimates for food groups for interpretability. The sum totals of nutrient
712 constituents were excluded to avoid redundancy in the PCA.

713 In the VDAART cohort, mothers were asked to complete a semi-quantitative food frequency
714 questionnaire (FFQ) during the clinical visit corresponding to when the blood metabolome samples were
715 taken: 10-18 weeks and 32-38 weeks gestation (59). The FFQ captured the average weekly
716 consumption of each food item(s) over the past year using the following ordinal categories: "Less than
717 once per week" as 0, "Once per week" as 1, "2-4 times per week" as 2, "Nearly daily or daily" as 3, and
718 "Twice or more per day" as 4.

719 **DNBC, VDAART and COPSAC2000 Neurodevelopmental Outcomes**

720 In the DNBC cohort, neurodevelopmental outcomes were derived from National registers. Specifically,
721 outcome data was extracted from the Danish National Patient Register (60), the Danish Psychiatric
722 Central Research Register (61), the Danish National Prescription Registry (62). Children were defined
723 as having an ADHD diagnosis if they had received an ADHD diagnosis or redeemed a prescription for
724 ADHD medication after reaching 3 years of age. The diagnoses were obtained from the Danish National
725 Patient Register and Danish Psychiatric Central Research Register. These were recorded according to
726 the International Classification of Diseases Tenth revision (ICD-10) and we defined a case by using the
727 diagnostic codes from F90.x. Prescriptions of ADHD medication were identified from the Danish
728 National Prescription Registry using the Anatomical Therapeutic Chemical Classification codes for
729 methylphenidate (N06BA04), modafinil (N06BA07), and atomoxetine (N06BA09). Similarly, autism
730 diagnosis was defined as children aged 2 years or older with a diagnosis code of ICD-10: F84.0, F84.1,
731 F84.5, F84.8, or F84.9, derived from the Danish National Patient Register, or the Danish Psychiatric
732 Central Research Register. Any neurodevelopmental diagnosis disorder was defined as having an
733 ADHD, or autism diagnosis, as defined above, or any of the following ICD-10 codes: F80-83 (other
734 developmental disorder), F84 (Pervasive developmental disorders), (F88-89 (other/unspecified
735 disorders of psychological development), F95 (tic disorders), F98·8 (ADHD – inattentive type) and F20-
736 F29 (schizophrenia spectrum disorder). In addition, at 7 years, we evaluated hyperactivity/inattention
737 problems using the subscale from the SDQ, which scores range from 0 to 10 (49,50).

738 Parents of VDAART children at the six-, seven- and eight-year follow-up visits were asked if their child
739 “had ever received a physician diagnosis of ADD or ADHD” or “had ever received a physician diagnosis
740 of autism”. Our main analysis was on children at the age of 6. Further for an analysis of robustness we
741 assessed associations on whether children had ever had a diagnosis of ADD/ADHD or autism up to the
742 age of eight.

743 In COPSAC2000, participants were asked to complete the Adult ADHD Self-Report Scale v1.1 (ASRS)
744 at the 18-year clinical cohort visit (63). The ASRS has been validated and demonstrated good reliability
745 and validity in screening for ADHD in adults. In our analysis, participants received a score of 1 for any
746 question that deemed a symptom of ADHD (such that total scores could range from 0 to 18) (64). As a
747 subanalysis we stratified inattention-based questions (Q1-Q4, Q7-Q11) and hyperactivity-impulsivity
748 questions (Q5-Q6, Q12-Q18).

749 **Blood Metabolome**

750 Untargeted plasma metabolomics data was collected from mothers at mid-pregnancy (24 weeks
751 gestation) and one week postpartum, and from children at ages 6 months, 18 months, and 6 years in
752 the COPSAC2010 cohort. A blood sample was collected using an EDTA tube during the visit to the
753 research clinic site, then centrifuged for 10 minutes at 4000 rpm to extract the plasma. The supernatant
754 was secured and stored at -80°C for future analysis. The untargeted metabolomic analysis of the
755 plasma samples for both COPSAC2010 and the VDAART cohorts were carried out by Metabolon, Inc.
756 (NC, USA).

757 For sample preparation, we employed the MicroLab STAR® system from Hamilton Company, which is
758 an automated process. Each sample was enhanced with recovery standards to ensure quality control
759 (QC) before metabolites were extracted using methanol. This extraction process involved vigorous
760 shaking for 2 minutes using a Glen Mills GenoGrinder 2000, followed by centrifugation, to precipitate
761 proteins. The extract was then divided into four aliquots for further analysis on four different LC-MS/MS
762 platforms. The aliquots were dried using a TurboVap® (Zymark) to evaporate the organic solvent, then
763 stored under nitrogen overnight prior to LC-MS/MS preparation.

764 The analysis through LC-MS/MS was conducted using an ACQUITY Ultra-Performance Liquid
765 Chromatography (UPLC) system by Waters, Milford, USA, coupled with a Q Exactive™ Hybrid

766 Quadrupole-Orbitrap™ mass spectrometer, which includes a heated electrospray ionisation (HESI-II)
767 source, provided by ThermoFisher Scientific, Waltham, Massachusetts, USA. We prepared the sample
768 extracts in solvent mixes specifically chosen for each of the four LC methods applied: two methods
769 were reverse phase UPLC-ESI(+) MS/MS for analysing both hydrophilic and hydrophobic molecules;
770 another was a reverse phase UPLC-(-) MS/MS; and the last was HILIC/UPLC-(-) MS/MS. The mass
771 spectrometry analysis alternated between full scan MS and data-dependent MS_n scans with dynamic
772 exclusion, covering a scan range from 70 to 1000 m/z for both ion modes.

773 In terms of data collection and quality control, the raw data was subjected to extraction, peak
774 identification and followed by QC procedures. The semi-quantification of samples was based on the
775 area-under-the-curve method. Further details are discussed in our previously published work (65).

776 Data preprocessing was done by excluding metabolites with >33% missingness. Remaining missing
777 data was imputed using random forest imputation (missForest package, v1.5) (66) and the metabolome
778 data was log-transformed, centred and scaled, prior to analysis. A pattern of missingness identified in
779 the metabolite subset (0.11 [0.02-0.20], p=0.021) suggested under detection in the Western dietary
780 pattern, with no corresponding bias for neurodevelopmental outcomes or across the full metabolome
781 (*Table S13*), reinforcing the validity of our imputation approach. The metabolome data for mothers at
782 mid-pregnancy (24 weeks gestation) had a total of 760 annotated metabolites for analysis. Of these,
783 744 metabolites overlapped between the 24-week gestation period and one week postpartum, 516
784 metabolites overlapped with 6-month data, 707 metabolites overlapped with 18-month data and 540
785 metabolites overlapped with 6-year data.

786 We used two VDAART blood metabolome pregnancy time points (10-18 weeks and 32-38 weeks),
787 measured on the same platform as the COPSAC2010 samples, to replicate our findings for ADHD. The
788 24-week pregnancy time point in COPSAC2010 was compared with those for early pregnancy (10-18
789 weeks gestation) and late pregnancy (32-38 weeks gestation) in VDAART, identifying 640 and 689
790 overlapping metabolites, respectively. We further predicted metabolite scores for the VDAART children,
791 with 523 overlapping metabolites at 1 year, 530 at 3 years, and 677 overlapping metabolites at 6 years.
792 The metabolite scores were predicted using the model trained on COPSAC2010 data; applied to log-
793 transformed, centred and scaled VDAART data. The metabolite score predictions were subsequently
794 scaled, and thus results should be interpreted as per SD change in the given population.

795 **Neonatal Dried Blood Spot samples**

796 DBS samples from COPSAC2010 ($n=677$) and COPSAC2000 ($n=387$) were respectively collected at
797 age 2-3 days and 1-12 days after birth, and stored at -20°C at the Danish National Biobank until
798 analysis. Metabolic profiles of the DBS samples were acquired by liquid chromatography mass
799 spectrometry (LC-MS). Data preprocessing was executed using both XCMS and MZmine, with the
800 quality assessed based on the distribution of pooled samples (38). Metabolite extraction from DBS
801 samples, a 3.2mm punch in diameter, was conducted using a Microlab STAR automated liquid handler
802 from Hamilton Bonaduz AG, Bonaduz, Switzerland. These samples were extracted onto 96-well plates
803 in batches with 100 μL of 80% methanol, specifically designed for analytical processes. Subsequently,
804 75 μL of the supernatants were shifted to fresh plates, air-dried under a nitrogen atmosphere, and
805 reconstituted in 75 μL of 2.5% methanol. Before injection, 65 μL was transferred onto the final plates.
806 For the analysis, samples from both COPSAC2000 and COPSAC2010 were divided, with the former
807 distributed across six batches and the latter across ten. Each batch or plate comprised eight water
808 blanks, an internal standard mix, four external controls, three paper blanks, four pooled samples, two
809 diluted pools, and 74 cohort samples. All extractions utilised LC-MS grade solvents provided by Thermo
810 Fisher Scientific, Waltham, MA, USA. An addition of 24 isotope-labelled internal standards,
811 encompassing amino acids and acylcarnitines, was made to the extraction solvents. These standards,
812 consistent in concentration across samples, were employed to ensure quality and evaluate the efficacy
813 of batch correction and normalisation that followed. To further gauge the variability in sample
814 preparation, acquisition, and preprocessing, quality control pooled samples (PSs) were periodically
815 assessed throughout the analysis run. Metabolic profiles were generated using a high-resolution
816 Thermo Scientific Q-Exactive Orbitrap mass spectrometer, linked to a Dionex Ultimate 3000 UPLC.
817 This complex procedure involved a series of specific injection, gradient operation, and parameters for
818 mass spectrometric analysis. Preprocessing of the acquired data involved the use of software like
819 XCMS, MZmine, and MSconvert, with specific protocols established for peak detection, alignment,
820 deconvolution, and filtering. Ensuring data quality was paramount, and this was maintained through the
821 use of internal standards and a series of checks, including principal component analysis (PCA) to
822 confirm the clustering of pooled samples. For a more detailed insight into the equipment settings, data
823 preprocessing steps, and quality controls, refer to the specific sections on mass spectrometry settings,
824 LC-MS/MS data preprocessing, and quality control in the supplementary information. Further in-depth

825 description of sample preparation, LC-MS metabolic profiling, and data pre-processing for both cohorts
826 can be found in previous work (38). There were 2313 features detected in COPSAC2010 and 2363
827 features in COPSAC2000. As the majority of features were unnamed, we merged both datasets using
828 an inexact matching criterion (mass ± 0.01 , retention time ± 0.1) using the fuzzyjoin R package (v0.1.6)
829 (67) and subsequently found 1253 overlapping metabolites between cohorts. For further robustness,
830 we applied a further filter, only retaining features that had a cross-correlation between cohorts of >0.4 ,
831 ending with 951 overlapping features between cohorts.

832 **Information on Covariates**

833 In our multivariable analysis, we included the following covariates for COPSAC2010: pre-pregnancy
834 maternal BMI, social circumstances (the first principal component of household income, maternal
835 education level, and maternal age at birth), child sex, birth weight, gestational age, smoking during
836 pregnancy, antibiotic use during pregnancy, pre-eclampsia and a child Western dietary pattern,
837 assessed by a FFQ from children at 10 years old. Missing covariate data was imputed, based on the
838 available covariate information available using the imputePCA function with one component from the
839 missMDA (v1.18) R package.

840 Additionally, we conducted sensitivity analysis in COPSAC2010 to explore the influence of the following
841 variables: the results of two randomised controlled trials conducted within the COPSAC2010 cohort
842 (n3-LCPUFA supplementation and high-dose vitamin D during pregnancy) (42), total energy intake
843 derived from the maternal FFQ, maternal ADHD genetic risk, intake of prenatal supplements, and
844 genomic PCs. Specifically, adjustment of intake of prenatal supplements was conducted by adjusting
845 for the first seven principal components (explaining 78.6% of the total variance) of the estimated intakes
846 of 31 vitamins, minerals and fatty acids, recorded at the time of the 24 week FFQ, and whether prenatal
847 supplements were taken (yes (94.1%) or no (5.9%)). Missing data were imputed using the same
848 approach described above from the missMDA R package.

849 Covariates used in multivariable analysis for the DNBC included pre-pregnancy maternal BMI, parental
850 social group (high, medium, skilled, student, unskilled, unemployed), maternal age, child sex, birth
851 weight, gestational age and smoking during pregnancy. Missing covariate data were imputed based on

852 existing covariates using multiple imputation as implemented by the PROC MI procedure in SAS
853 (version 9.1, SAS Institute, Cary, NC).

854 Covariates used in multivariable analysis for the VDAART included pre-pregnancy maternal BMI, social
855 circumstances (the first principal component of household income, maternal education level, and
856 maternal age at birth), child sex, birth weight, gestational age, smoking during pregnancy, pre-
857 eclampsia, and race. Missing covariate data was imputed, based on the available covariate information
858 using the imputePCA function with one component from the missMDA (v1.18) R package.

859 Covariates used in multivariable analysis for COPSAC2000 included social circumstances (the first
860 principal component of household income, maternal education level, and maternal age at birth), child
861 sex, birth weight, antibiotics during pregnancy and smoking during pregnancy.

862 The child sex variable in COPSAC2010, the DNBC, COPSAC2000 and VDAART was interpreted as
863 sex assigned at birth.

864 **Polygenic Risk Scores**

865 Maternal and child genotypes in the COPSAC2010 cohort were analysed using the Illumina Infinium
866 HumanOmniExpressExome BeadChip. To calculate PRS for ADHD and autism, we used data from
867 genome-wide association meta-analyses of diagnosed ADHD cases ($n=20,183$) and controls
868 ($n=35,191$) (68) and autism cases ($n=18,381$) and controls ($n=27,969$) (69).

869 The software package Polygenic risk score continuous shrinkage (CS) was used for PRS construction
870 through regularising SNP effects using a shrinkage prior (70). PRS-CS uses a linkage disequilibrium
871 (LD) reference panel constructed via European ancestry samples from the 1000 genomes project. We
872 used the automatic estimation of the polygenicity parameter (ϕ). Subsequent to SNP effect adjustment
873 with PRS-CS, we used the software PLINK2 (71) to aggregate SNP effects into PRSs for each
874 individual. The scores were scaled to mean 0 and SD 1 for each phenotype.

875 **Statistical Analysis**

876 Logistic regression models were used to determine the associations of maternal dietary patterns on
877 neurodevelopmental disorders, and linear regression models were used to assess the associations of

878 maternal dietary patterns on parentally reported symptom loads for ADHD and autism. All multivariable
879 models were adjusted for the previously mentioned covariates. Dietary principal components and
880 metabolite scores were scaled to enhanced interpretation (Odds ratios and estimates are interpreted
881 as per SD change). We used linear interaction models to examine the modulating effects of genetics,
882 child sex and maternal BMI on neurodevelopmental outcomes. All interaction models were multivariable
883 (see `Information on covariates`), additionally including genetic risk (see `Polygenic Risk Scores`). We
884 excluded five individuals from the analysis. Specifically, we removed the second twin from twin pairs
885 since the exposure of interest was not independent. However, non-twin sibling pairs were retained in
886 the analysis, as the exposure and outcome measures were independently assessed for each sibling.

887 We used Gaussian graphical network models via the framework described by Williams and Rast (72).
888 Gaussian graphical models show the non-zero relationships (95% CI) between the dietary pattern,
889 neurodevelopmental outcomes and model covariates, controlling for the linear effects of all covariates
890 expressed as partial correlations. We integrated gestational age and birthweight to refine our Gaussian
891 graphical network models, as these variables are highly collinear (73). From these models, significant
892 associations in the resulting precision matrices were visualised as interconnected network diagrams
893 utilising the ggraph (v2.1.0), igraph (v1.2.11), and qgraph (v1.9.2) libraries in R.

894 We used the caret package (v6.0.90) to establish Western dietary pattern metabolite scores (WDP-
895 MS), via sparse partial least squares regression on the COPSAC2010 metabolomics datasets, with the
896 pregnancy Western dietary pattern as the response. Individual models were created for predicting
897 WDP-MS at other timepoints, using the subset of overlapping metabolites (See `Blood Metabolome`).
898 To improve interpretability and reduce the risk of overfitting, we used single-component models,
899 applying cross-validated predictions (repeated cv, number of segments=5, repeats=10). After reviewing
900 models that varied in sparsity (incremented by 0.1 from 0 to 1), we opted for the model with the lowest
901 root-mean-standard error for cross-validation (RMSECV) as our selection criteria. For external
902 validation between COPSAC2010 and VDAART, we adjusted our model parameters to balance against
903 overfitting whilst ensuring optimal performance, leading to the selection of models that were within +0.01
904 RMSECV of the best-performing model. We similarly trained a sPLS model in the COPSAC2010 cohort
905 on the Western dietary pattern from DBS metabolic profiles that overlapped with the COPSAC2000
906 cohort.

907 To elucidate the role of metabolites as potential biomarkers or mediators in the association between a
908 Western dietary pattern and neurodevelopmental disorders, we employed a systematic backward
909 elimination strategy. This approach was designed to iteratively exclude metabolites, aiming to identify
910 those with the most profound mediating influence on the outcome. We employed 10,000 iterations for
911 each step of this elimination. We used two linear models: one linking a composite metabolite score to
912 the Western dietary pattern and covariates, and another assessing its mediating role between dietary
913 patterns and neurodevelopmental outcome. This causal mediation analysis was conducted with the
914 mediation package in R (v4.5.0).

915 When comparing the associations of the mother and child WDP-MS in logistic regression, we utilised
916 the imputePCA function from the missMDA package (v1.18) (74) to impute missing data with one
917 component (12.5% in COPSAC2010). This was done using the available metabolite scores as a
918 reference. Linear mixed models with variable slopes and intercepts were applied to the WDP-MS data,
919 integrating gestational age alongside chronological age. The slopes and intercepts were treated as
920 random effects, allowing for modelling of the longitudinal association of the identified maternal dietary
921 pattern on neurodevelopmental outcomes. Accordingly, the random effects were extracted for
922 inference, the "lme4" R- package (1.1.28) was used for modelling (75), both slopes and intercepts were
923 scaled (estimates are interpreted as per SD change).

924 A significance level of 0.05 was used in all analyses and false-discovery rate control (FDR) applied
925 where relevant (<0.05). All data analyses were performed with the statistical software R version 4.1.1.
926 Other R packages utilised in this analysis include tidyverse (v1.3.1), dplyr (v1.0.10), broom (v0.7.12),
927 lubridate (v1.8.0), ggpubr (v0.4.0) and tableone (v0.13.0).

928 **Data Availability:** Participant-level personally identifiable data are protected under the Danish Data
929 Protection Act and European Regulation 2016/679 of the European Parliament and of the Council
930 (GDPR) that prohibit distribution even in pseudo-anonymized form. However, participant-level data can
931 be made available under a data transfer agreement as part of a collaboration effort.

932 **Code Availability:** The custom code employed in this research is freely accessible to the public for
933 transparency and reproducibility purposes.



934 **Methods-only References**

- 935 42. Bisgaard H, Vissing NH, Carson CG, Bischoff AL, Følsgaard NV, Kreiner-Møller E, et al.
936 Deep phenotyping of the unselected COPSAC 2010 birth cohort study [Internet]. Vol. 43, *Clinical &*
937 *Experimental Allergy*. 2013. p. 1384–94. Available from: <http://dx.doi.org/10.1111/cea.12213>
- 938 43. Mohammadzadeh P, Rosenberg JB, Vinding R, Møllegaard Jepsen JR, Lindberg U,
939 Følsgaard N, et al. Effects of prenatal nutrient supplementation and early life exposures on
940 neurodevelopment at age 10: a randomised controlled trial - the COPSYPH study protocol. *BMJ*
941 *Open*. 2022 Feb 1;12(2):e047706.
- 942 44. Olsen J, Melbye M, Olsen SF, Sørensen TI, Aaby P, Andersen AM, et al. The Danish National
943 Birth Cohort—its background, structure and aim. *Scand J Public Health*. 2001 Dec;29(4):300–7.
- 944 45. Olsen SF, Mikkelsen TB, Knudsen VK, Orozova-Bekkevold I, Halldórsson TI, Strøm M, et al.
945 Data collected on maternal dietary exposures in the Danish National Birth Cohort. *Paediatr*
946 *Perinat Epidemiol*. 2007 Jan;21(1):76–86.
- 947 46. Litonjua AA, Lange NE, Carey VJ, Brown S, Laranjo N, Harshfield BJ, et al. The Vitamin D
948 Antenatal Asthma Reduction Trial (VDAART): rationale, design, and methods of a randomized,
949 controlled trial of vitamin D supplementation in pregnancy for the primary prevention of asthma
950 and allergies in children. *Contemp Clin Trials*. 2014 May;38(1):37–50.
- 951 47. Kelly RS, Boulin A, Laranjo N, Lee-Sarwar K, Chu SH, Yadama AP, et al. Metabolomics and
952 Communication Skills Development in Children; Evidence from the Ages and Stages
953 Questionnaire. *Metabolites* [Internet]. 2019 Mar 5;9(3). Available from:
954 <http://dx.doi.org/10.3390/metabo9030042>
- 955 48. Bisgaard H. The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): design,
956 rationale, and baseline data from a longitudinal birth cohort study. *Ann Allergy Asthma Immunol*.
957 2004 Oct;93(4):381–9.
- 958 49. Obel C, Heiervang E, Rodriguez A, Heyerdahl S, Smedje H, Sourander A, et al. The
959 Strengths and Difficulties Questionnaire in the Nordic countries. *Eur Child Adolesc Psychiatry*.
960 2004;13 Suppl 2:II32–9.
- 961 50. Sveen TH, Berg-Nielsen TS, Lydersen S, Wichstrøm L. Detecting psychiatric disorders in
962 preschoolers: screening with the strengths and difficulties questionnaire. *J Am Acad Child*
963 *Adolesc Psychiatry*. 2013 Jul;52(7):728–36.
- 964 51. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective
965 Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-
966 PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry*. 1997 Jul;36(7):980–8.
- 967 52. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders:*
968 *DSM-5-TR*. 2022. 1120 p.
- 969 53. World Health Organization. *The International Statistical Classification of Diseases and Health*
970 *Related Problems ICD-10: Tenth Revision. Volume 2: Instruction Manual*. World Health
971 Organization; 2004. 198 p.
- 972 54. Friis S, Kruger Kjaer S, Stripp C, Overvad K. Reproducibility and relative validity of a self-
973 administered semiquantitative food frequency questionnaire applied to younger women. *J Clin*
974 *Epidemiol*. 1997 Mar;50(3):303–11.
- 975 55. Mikkelsen TB, Olsen SF, Rasmussen SE, Osler M. Relative validity of fruit and vegetable
976 intake estimated by the food frequency questionnaire used in the Danish National Birth Cohort.
977 *Scand J Public Health*. 2007;35(2):172–9.
- 978 56. Mikkelsen TB, Osler M, Olsen SF. Validity of protein, retinol, folic acid and n-3 fatty acid
979 intakes estimated from the food-frequency questionnaire used in the Danish National Birth


- 980 Cohort. *Public Health Nutr.* 2006 Sep;9(6):771–8.
- 981 57. Paperpile [Internet]. [cited 2023 Oct 26]. Danish Food Composition Data, Version 7. Available
982 from: <https://paperpile.com/app/p/49f46071-353d-0183-9823-b8b1c9c5898d>
- 983 58. Bjerregaard AA, Halldorsson TI, Kampmann FB, Olsen SF, Tetens I. Relative validity of a
984 web-based food frequency questionnaire for Danish adolescents. *Nutr J.* 2018 Jan 12;17(1):9.
- 985 59. Kachroo P, Kelly RS, Mirzakhani H, Lee-Sarwar K, Chawes BL, Blighe K, et al. Fish oil
986 supplementation during pregnancy is protective against asthma/wheeze in offspring. *J Allergy
987 Clin Immunol Pract.* 2020 Jan;8(1):388–91.e2.
- 988 60. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The
989 Danish National Patient Registry: a review of content, data quality, and research potential. *Clin
990 Epidemiol.* 2015 Nov 17;7:449–90.
- 991 61. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. *Scand
992 J Public Health.* 2011 Jul;39(7 Suppl):54–7.
- 993 62. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data
994 Resource Profile: The Danish National Prescription Registry. *Int J Epidemiol.* 2017 Jun
995 1;46(3):798–798f.
- 996 63. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health
997 Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the
998 general population. *Psychol Med.* 2005 Feb;35(2):245–56.
- 999 64. Adler LA, Faraone SV, Sarocco P, Atkins N, Khachatryan A. Establishing US norms for the
1000 Adult ADHD Self-Report Scale (ASRS-v1.1) and characterising symptom burden among adults
1001 with self-reported ADHD. *Int J Clin Pract.* 2019 Jan;73(1):e13260.
- 1002 65. Rago D, Rasmussen MA, Lee-Sarwar KA, Weiss ST, Lasky-Su J, Stokholm J, et al. Fish-oil
1003 supplementation in pregnancy, child metabolomics and asthma risk. *EBioMedicine.* 2019
1004 Aug;46:399–410.
- 1005 66. Stekhoven DJ, Bühlmann P. MissForest--non-parametric missing value imputation for mixed-
1006 type data. *Bioinformatics.* 2012 Jan 1;28(1):112–8.
- 1007 67. Website [Internet]. Available from: Robinson D Bryan J Elias. 2020. “Fuzzyjoin: Join Tables
1008 Together on Inexact Matching. 2020” Version 0.1.6 (May). [https://cran.r-
1009 project.org/web/packages/fuzzyjoin/index.html](https://cran.r-project.org/web/packages/fuzzyjoin/index.html).
- 1010 68. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the
1011 first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nat Genet.* 2019
1012 Jan;51(1):63–75.
- 1013 69. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common
1014 genetic risk variants for autism spectrum disorder. *Nat Genet.* 2019 Mar;51(3):431–44.
- 1015 70. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression
1016 and continuous shrinkage priors. *Nat Commun.* 2019 Apr 16;10(1):1776.
- 1017 71. PLINK 2.0 [Internet]. [cited 2023 Mar 29]. Available from: [https://www.cog-
1018 genomics.org/plink/2.0/](https://www.cog-genomics.org/plink/2.0/)
- 1019 72. Williams DR, Rast P. Back to the basics: Rethinking partial correlation network methodology.
1020 *Br J Math Stat Psychol.* 2020 May;73(2):187–212.
- 1021 73. Marsál K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves
1022 based on ultrasonically estimated foetal weights. *Acta Paediatr.* 1996 Jul;85(7):843–8.
- 1023 74. Josse J, Husson F. **missMDA**: A Package for Handling Missing Values in Multivariate Data
1024 Analysis [Internet]. Vol. 70, *Journal of Statistical Software.* 2016. Available from:

1025 <http://dx.doi.org/10.18637/jss.v070.i01>



1026 75. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using **lme4**
1027 [Internet]. Vol. 67, Journal of Statistical Software. 2015. Available from:
1028 <http://dx.doi.org/10.18637/jss.v067.i01>




Neurodevelopmental Diagnosis
 No
 Yes




Supplementary Figure S1. Biplot of the first two principal components (PCs) from the maternal food frequency questionnaire-derived nutrient constituents. PC2 (Western dietary pattern) is significantly associated with any neurodevelopmental disorder (OR 1.53 [1.17 - 2.00], $p=0.002$), ADHD (OR 1.66 [1.21 - 2.27], $p = 0.002$), and autism diagnosis (OR 2.22 [1.33 - 3.74], $p = 0.002$). PC1 is not significantly associated with any neurodevelopmental disorders ($p > 0.288$). Further details of the loadings for each of the 95 nutrient constituents can be viewed in supplementary table 2.




Supplementary Figure S2. Biplot of the first two principal components from the maternal FFQ-derived nutrient constituents **A)** Nutrient constituents are categorised into fatty acids, amino acids, sugars, minerals and vitamins. Fatty acids are a key determinant of PC2 (Western dietary pattern) **B)** Stratified further by fatty acid type, saturated fatty acids are most associated with PC2 (Western dietary pattern).




Cohorts • COPSAC2010 24 weeks Pregnancy • VDAART 10–18 weeks Pregnancy




Cohorts • COPSAC2010 24 weeks Pregnancy • VDAART 32–38 weeks Pregnancy




Metabolites 622 Remaining Metabolites 18 Metabolite Score Metabolites



Metabolites 622 Remaining Metabolites 18 Metabolite Score Metabolites





Metabolites 670 Remaining Metabolites 19 Metabolite Score Metabolites



Metabolites 670 Remaining Metabolites 19 Metabolite Score Metabolites


Supplementary Figure S3. Comparison of maternal blood metabolomes at three different pregnancy timepoints from two mother-child cohorts. Top panels show a Principal Component Analysis (PCA) scoreplot on all metabolites, as well as the selected metabolite scores for the COPSAC2010 vs VDAART 10-18 weeks (left) and COPSAC2010 vs VDAART 32-38 weeks (right). Bottom panels show the relative variation per metabolite computed by the ratio of sums of squares ($SSQ_{\text{line}} / SSQ_{\text{residual}}$) from a one-way anova model with Time/Cohort at predictor and Comparison of per metabolite standard deviation within cohort relative to 24 week gestation pregnancy time point from COPSAC2010 for the COPSAC2010 vs VDAART 10-18 weeks (left) and COPSAC2010 vs VDAART 32-38 weeks (right).

VDAART Pregnancy FFQs Associate with Western Dietary Pattern Metabolite Scores






Supplementary Figure S4. Associations between dietary intake from food frequency questionnaires (FFQs) during pregnancy and Western Dietary Pattern Metabolite Scores (WDP-MS) at two distinct timepoints (10-18 weeks and 32-38 weeks) in the VDAART cohort. The depicted associations, based on the VDAART cohort, were assessed using COPSAC2010 cohort-trained models that shared overlapping metabolites.

ADHD Mediation by Metabolites: Models Based on COPSAC2010 with VDAART Timepoints







Supplementary Figure S5. Metabolites associated with a Western dietary pattern at VDAART gestational timepoints (10-18 weeks and 32-38 weeks), based on models from the COPSAC2010 cohort. The selected metabolite scores are depicted by bars, distinguished by their metabolic pathway. Striped bars indicate metabolites that mediate the association with ADHD Diagnosis in COPSAC2010, while solid bars signify non-mediating metabolites. The directionality of the bars represents the positive or negative metabolite score. Metabolite scores from VDAART are colour-coded for each timepoint: 10-18 weeks (green) and 32-38 weeks (purple).







Supplementary Figure S6. Comparative analysis of metabolomic data across newborn dry blood spots from the COPSAC2010 and COPSAC2000 mother-child cohorts. Principal Component Analysis (PCA) plots illustrate the distribution and separation of metabolomic data between cohorts. Panels A-C represent overlapping metabolomes used in our analysis (n=951, n=774, n=626), showcasing subsets of metabolites selected based on varying degrees of correlation and distributional similarity between cohorts. **A:** displays the PCA for metabolites with correlations greater than 0.4 (n=951), **B:** Correlations greater than 0.6 (n=774), and **C:** Metabolites with a correlation greater than 0.6 passing the two-sample Kolmogorov-Smirnov test with a threshold of ≥ 0.05 (n=626).

Sex Stratified: Western Dietary Pattern Associations with Neurodevelopmental Disorders









Supplementary Figure S7. Modulation of the Western Dietary Pattern, Stratified by Child Sex, on Neurodevelopmental Outcomes. Odds ratio estimates of ADHD (**A**) and autism diagnoses (**B**) based on interactions of the Western dietary pattern, maternal pre-pregnancy BMI (split at median value 23.7), and child's polygenic risk score (PRS) (median split) for ADHD and autism, stratified by child sex. Estimates for ADHD and autism symptom loads based on the Western dietary pattern, considering tertiles of maternal pre-pregnancy BMI (<22.2, 22.2-25.4, >25.4) and child's PRS for ADHD and autism, stratified by child sex. Stars represent significance levels: * indicates $p < 0.05$, ** indicates $p < 0.01$, and *** indicates $p < 0.001$, with "NS" denoting non-significant results ($p \geq 0.05$). Further details, including the individual associations of these modulating factors, can be found in Table S11.

Western Dietary Pattern Metabolite Score Associations with Neurodevelopmental Disorders



Supplementary Figure S8. Modulation of the Western Dietary Pattern Metabolite Score on Neurodevelopmental Outcomes in COPSAC2010 Cohort. Odds ratio estimates for ADHD (A) and autism diagnoses (B) based on interactions of the Western dietary pattern metabolite score, maternal pre-pregnancy BMI (split at median value 23.7), and child's polygenic risk score (PRS) (median split) for ADHD and autism. Estimates for ADHD (C) and autism (D) symptom loads are based on the Western dietary pattern metabolite score, considering tertiles of maternal pre-pregnancy BMI and child's PRS for ADHD and autism. Stars represent significance levels: * indicates $p < 0.05$, ** indicates $p < 0.01$, and *** indicates $p < 0.001$, with "NS" denoting non-significant results ($p \geq 0.05$). Further details, including the individual associations of these modulating factors, can be found in Table S11.



Supplementary Figure S9. The Western dietary patterns metabolite scores association with ADHD and autism symptom loads, considering standard clinical classifications of maternal pre-pregnancy BMI. Panels A and D represent ADHD and autism symptom loads respectively, stratified by low/high genetic risk (median cut). Panels B and E further contextualise these associations based on maternal pre-pregnancy BMI categories. Panels C and F again contextualise these associations by stratifying by child sex (male sex shown).

Cohort Characteristics	Participated	Not Participated
n =	600	95
Age (mean (SD))	10.3 (0.4)	-
Male Sex (%)	310 (51.7)	47 (49.5)
Caucasian Race (%)	573 (95.5)	93 (97.9)
Income type (%)		
Low (<50,000 euro)	48 (13.0)	12 (18.2)
Medium (50,000 - 110,000 euro)	114 (31.0)	17 (25.8)
High (>110,000 euro)	206 (56.0)	37 (56.1)
Maternal Education Level at Birth		
Low (primary, secondary, or college graduate)	46 (7.7)	5 (5.3)
Medium (tradesman or bachelor's degree)	373 (62.2)	68 (71.6)
High (Masters degree)	181 (30.2)	22 (23.2)
Maternal age at birth (mean (SD))	32.4 (4.3)	31.8 (4.5)
Birthweight (mean (SD))	3.5 (0.5)	3.5 (0.6)
Gestational age (mean (SD))	279 (12)	278 (11)
Cesarean section (%)	125 (20.8)	25 (26.3)
Maternal smoking during pregnancy (%)	44 (7.3)	10 (10.5)
Solely Breastfed (mean (SD))	105 (59)	94 (65)
Siblings (mean (SD))	1.6 (0.9)	1.6 (0.8)
Pregnancy Western Dietary Pattern (mean (SD))	0.02 (0.99)	-0.20 (1.04)
Pregnancy Western Dietary Pattern Metabolite Score (mean (SD))	-0.02 (0.99)	0.10 (1.04)

Supplementary Table S1. Cohort characteristics stratified by participation in the COPSAC2010 10 year clinical visit. Low, medium, and high income are defined as <50,000, 50,000 - 110,000, and >110,000 euro respectively. Low, medium and high level educational attainment are defined as “primary, secondary, or college graduate”, “tradesman or bachelor’s degree” and “Masters degree”, respectively.

Cohort Characteristics	Female	Male
n =	290	310
Age (mean (SD))	10.3 (0.4)	10.3 (0.3)
Caucasian Race (%)	279 (96.2)	294 (94.8)
Income type (%)		
Low (<50,000 euro)	30 (10.3)	18 (5.8)
Medium (50,000 - 110,000 euro)	152 (52.4)	168 (54.2)
High (>110,000 euro)	108 (37.2)	124 (40.0)
Maternal Education Level at Birth		
Low (primary, secondary, or college graduate)	24 (8.3)	22 (7.1)
Medium (tradesman or bachelor's degree)	172 (59.3)	201 (64.8)
High (Masters degree)	94 (32.4)	87 (28.1)
Maternal age at birth (mean (SD))	32.4 (4.2)	32.3 (4.5)
Birthweight (mean (SD))	3.5 (0.5)	3.6 (0.6)
Gestational age (mean (SD))	280 (10)	279 (12)
Cesarean section (%)	54 (18.6)	71 (22.9)
Maternal smoking during pregnancy (%)	22 (7.6)	22 (7.1)
Solely Breastfed (mean (SD))	106 (59)	104 (58)
Siblings (mean (SD))	1.6 (0.9)	1.6 (0.8)

Supplementary Table S2. Cohort characteristics stratified by child sex in COPSYPCH 10 year clinical visit. Low, medium, and high income are defined as <50,000, 50,000 - 110,000, and >110,000 euro, respectively. Low, medium and high level educational attainment are defined as “primary, secondary, or college graduate”, “tradesman or bachelor's degree” and “Masters degree”, respectively.

	Mean (SD)	PC1 Loadings	PC2 Loadings	Category
FFQ nutrient constituents	-	-	-	
Added sugar (g/day) (mean (SD))	36.04 (26.25)	0.033	0.123	Sugars
Dietary fiber (g/day) (mean (SD))	27.92 (9.76)	0.097	-0.125	Sugars
Alcohol (g/day) (mean (SD))	0.41 (0.75)	0.015	0.013	Sugars
Ashes (g/day) (mean (SD))	20.18 (4.99)	0.142	-0.018	Minerals
Water (g/day) (mean (SD))	2817.43 (740.48)	0.085	-0.072	Minerals
Vitamin A (RE/day) (mean (SD))	824.74 (368.58)	0.085	0.01	Vitamins
Retinol (µg/day) (mean (SD))	490.63 (241.14)	0.085	0.134	Vitamins
Betacarotene (µg/day) (mean (SD))	3958.40 (3258.49)	0.038	-0.106	Vitamins
Vitamin D (µg/day) (mean (SD))	4.86 (2.81)	0.071	-0.087	Vitamins
Vitamin D3 (cholecalciferol) (µg/day) (mean (SD))	1.11 (0.70)	0.08	-0.03	Vitamins
25-hydroxycholecalciferol - a metabolically activated form of cholecalciferol (Vitamin D3) (µg/day) (mean (SD))	0.03 (0.02)	0.048	0.086	Vitamins
Vitamin E (a-TE/day) (mean (SD))	7.93 (2.95)	0.099	-0.045	Vitamins
Alphatocoferol (mg/day) (mean (SD))	7.30 (2.82)	0.097	-0.044	Vitamins
Vitamin K (µg/day) (mean (SD))	86.50 (53.03)	0.052	-0.102	Vitamins
Vitamin B1 (thiamin) (mg/day) (mean (SD))	1.39 (0.38)	0.13	-0.063	Vitamins
Vitamin B2 (riboflavin) (mg/day) (mean (SD))	1.86 (0.66)	0.115	0.002	Vitamins
Niacin equivalent (NE/day) (mean (SD))	26.45 (6.40)	0.142	-0.045	Vitamins
Niacin (mg/day) (mean (SD))	14.49 (3.72)	0.126	-0.074	Vitamins
Tryptophan (mg/day) (mean (SD))	14.68 (4.00)	0.138	-0.004	Amino Acids
Vitamin B6 (mg/day) (mean (SD))	1.61 (0.42)	0.135	-0.111	Vitamins

Pantothenic acid (mg/day) (mean (SD))	6.24 (1.73)	0.134	-0.049	Vitamins
Biotin (µg/day) (mean (SD))	42.94 (13.22)	0.128	-0.068	Vitamins
Folate (µg/day) (mean (SD))	344.59 (101.24)	0.115	-0.108	Vitamins
Vitamin B12 (µg/day) (mean (SD))	5.64 (2.14)	0.116	-0.017	Vitamins
Vitamin C (mg/day) (mean (SD))	140.14 (71.37)	0.061	-0.138	Vitamins
L-ascorbic acid (mg/day) (mean (SD))	136.31 (65.88)	0.063	-0.14	Vitamins
L-dehydroascorbic acid (mg/day) (mean (SD))	13.79 (7.42)	0.05	-0.115	Vitamins
Sodium (mg/day) (mean (SD))	2956.73 (813.05)	0.124	0.043	Minerals
Potassium (mg/day) (mean (SD))	3584.14 (941.59)	0.131	-0.083	Minerals
Calcium (mg/day) (mean (SD))	1237.53 (454.19)	0.103	0.005	Minerals
Magnesium (mg/day) (mean (SD))	399.47 (108.31)	0.126	-0.106	Minerals
Phosphor (mg/day) (mean (SD))	1654.26 (460.76)	0.135	-0.03	Minerals
Iron (mg/day) (mean (SD))	11.22 (2.89)	0.124	-0.074	Minerals
Copper (mg/day) (mean (SD))	4.88 (1.52)	0.055	-0.095	Minerals
Zink (mg/day) (mean (SD))	12.01 (2.98)	0.141	-0.03	Minerals
Iodine (µg/day) (mean (SD))	302.03 (120.03)	0.092	-0.02	Minerals
Manganese (mg/day) (mean (SD))	5.23 (2.06)	0.09	-0.122	Minerals
Chromium (µg/day) (mean (SD))	32.41 (10.28)	0.107	-0.058	Minerals
Selenium (µg/day) (mean (SD))	47.23 (12.57)	0.137	-0.052	Minerals
Nickel (µg/day) (mean (SD))	149.55 (52.65)	0.088	-0.115	Minerals
Fructose (g/day) (mean (SD))	13.72 (6.81)	0.05	-0.158	Sugars
Glucose (g/day) (mean (SD))	12.98 (6.50)	0.052	-0.135	Sugars
Lactose (g/day) (mean (SD))	23.29 (15.87)	0.073	0.028	Sugars
Maltose (g/day) (mean (SD))	2.26 (1.19)	0.056	0.01	Sugars

Sucrose (g/day) (mean (SD))	27.99 (12.07)	0.056	-0.01	Sugars
Starch (g/day) (mean (SD))	99.95 (35.10)	0.09	-0.022	Sugars
C4:0 (Butyric acid, Butanoic acid) (g/day) (mean (SD))	0.97 (0.54)	0.081	0.244	Fatty Acids
C6:0 (Caproic acid, Hexanoic acid) (g/day) (mean (SD))	1.01 (0.58)	0.079	0.243	Fatty Acids
C8:0 (Caprylic acid, Octanoic acid) (g/day) (mean (SD))	0.57 (0.33)	0.079	0.232	Fatty Acids
C10:0 (Capric acid, Decanoic acid) (g/day) (mean (SD))	0.84 (0.46)	0.082	0.243	Fatty Acids
C12:0 (Lauric acid, Dodecanoic acid) (g/day) (mean (SD))	1.26 (0.54)	0.093	0.215	Fatty Acids
C14:0 (Myristic acid, Tetradecanoic acid) (g/day) (mean (SD))	3.17 (1.44)	0.09	0.233	Fatty Acids
C15:0 (Pentadecylic acid, Pentadecanoic acid) (g/day) (mean (SD))	0.01 (0.01)	0.041	-0.018	Fatty Acids
C16:0 (Palmitic acid, Hexadecanoic acid) (g/day) (mean (SD))	15.63 (5.31)	0.106	0.202	Fatty Acids
C17:0 (Margaric acid, Heptadecanoic acid) (g/day) (mean (SD))	0.02 (0.01)	0.043	-0.006	Fatty Acids
C18:0 (Stearic acid, Octadecanoic acid) (g/day) (mean (SD))	6.70 (2.56)	0.095	0.195	Fatty Acids
C20:0 (Arachidic acid, Eicosanoic acid) (g/day) (mean (SD))	0.11 (0.06)	0.08	0.154	Fatty Acids
C22:0 (Behenic acid, Docosanoic acid) (g/day) (mean (SD))	0.05 (0.04)	0.046	0.01	Fatty Acids
C24:0 (Lignoceric acid, Tetracosanoic acid) (g/day) (mean (SD))	0.03 (0.03)	0.039	-0.091	Fatty Acids
C14:1, n-5 (Myristoleic acid) (g/day) (mean (SD))	0.37 (0.17)	0.083	0.231	Fatty Acids
C16:1, n-7 (Palmitoleic acid) (g/day) (mean (SD))	1.27 (0.38)	0.11	0.144	Fatty Acids
C18:1, n-9 (Oleic acid, Elaidic acid) (g/day) (mean (SD))	22.76 (7.61)	0.112	0.125	Fatty Acids
C18:1, n-7 (Vaccenic acid) (g/day) (mean (SD))	0.12 (0.05)	0.089	-0.049	Fatty Acids
C20:1, n-11 (Gadoleic acid) (g/day) (mean (SD))	0.52 (0.21)	0.105	0.113	Fatty Acids
C22:1, n-9 (Erucic acid) (g/day) (mean (SD))	0.02 (0.04)	0.028	-0.041	Fatty Acids
C22:1, n-11 (Cetoleic acid) (g/day) (mean (SD))	0.14 (0.17)	0.05	-0.063	Fatty Acids
C24:1, n-9 (Nervonic acid) (g/day) (mean (SD))	0.02 (0.02)	0.061	-0.09	Fatty Acids
C18:2, n-6 (Linoleic acid) (g/day) (mean (SD))	9.44 (3.25)	0.108	-0.019	Fatty Acids

C18:3, n-3 (Alpha-linolenic acid ALA) (g/day) (mean (SD))	1.92 (0.72)	0.107	0.018	Fatty Acids
C18:4, n-3 (Stearidonic acid SDA, Moroctic acid) (g/day) (mean (SD))	0.05 (0.05)	0.057	-0.08	Fatty Acids
C20:4, n-6 (Arachidonic acid AA) (g/day) (mean (SD))	0.05 (0.02)	0.074	-0.026	Fatty Acids
C20:5, n-3 (Eicosapentaenoic acid EPA, Timnodonic acid) (g/day) (mean (SD))	0.15 (0.11)	0.064	-0.117	Fatty Acids
C22:5, n-3 (Docosapentaenoic acid DPA, Clupanodonic acid) (g/day) (mean (SD))	0.04 (0.03)	0.063	-0.097	Fatty Acids
C22:6, n-3 (Docosahexaenoic acid DHA, Cervonic acid) (g/day) (mean (SD))	0.36 (0.24)	0.069	-0.102	Fatty Acids
Other fatty acids (g/day) (mean (SD))	0.17 (0.07)	0.087	-0.073	Fatty Acids
Trans fatty acids, total (g/day) (mean (SD))	1.61 (0.78)	0.084	0.24	Fatty Acids
Cholesterol (mg/day) (mean (SD))	306.56 (111.46)	0.104	0.143	Fatty Acids
Isoleucine (mg/day) (mean (SD))	3257.44 (895.38)	0.137	0.009	Amino Acids
Leucine (mg/day) (mean (SD))	5356.46 (1490.08)	0.136	0.011	Amino Acids
Lysine (mg/day) (mean (SD))	4771.66 (1352.94)	0.131	0.006	Amino Acids
Methionine (mg/day) (mean (SD))	1552.75 (421.81)	0.136	0.007	Amino Acids
Cystine (mg/day) (mean (SD))	667.43 (183.60)	0.134	-0.028	Amino Acids
Phenylalanine (mg/day) (mean (SD))	3059.71 (833.10)	0.138	0.004	Amino Acids
Tyrosine (mg/day) (mean (SD))	2295.78 (659.79)	0.133	0.014	Amino Acids
Threonine (mg/day) (mean (SD))	2615.14 (699.25)	0.139	-0.002	Amino Acids
Tryptophan (mg/day) (mean (SD))	802.48 (216.52)	0.138	0.004	Amino Acids
Valine (mg/day) (mean (SD))	4098.35 (1106.25)	0.138	0.005	Amino Acids
Arginine (mg/day) (mean (SD))	3814.66 (954.91)	0.138	-0.049	Amino Acids
Histidine (mg/day) (mean (SD))	1923.77 (502.98)	0.139	0.008	Amino Acids
Alanine (mg/day) (mean (SD))	3404.72 (833.44)	0.141	-0.023	Amino Acids
Asparagine acid (mg/day) (mean (SD))	6346.65 (1582.54)	0.141	-0.021	Amino Acids
Glutamic acid (mg/day) (mean (SD))	12803.38 (3446.26)	0.137	0.015	Amino Acids

Glycine (mg/day) (mean (SD))	2919.02 (713.39)	0.136	-0.023	Amino Acids
Proline (mg/day) (mean (SD))	4841.23 (1437.50)	0.13	0.031	Amino Acids
Serine (mg/day) (mean (SD))	3421.27 (925.75)	0.139	0.007	Amino Acids

Supplementary Table S3. Descriptive summary statistics for nutrients derived from maternal food frequency questionnaires in pregnancy and principal component loadings for principal component 1 and 2 in the COPSAC2010 cohort.

Supplement Intake at 24 Weeks Gestation	Mean (SD)	Taking Supplement
Vitamins	-	-
Vitamin A (µg) (mean (SD))	446.75 (256.98)	447
Vitamin B1, Thiamin (mg) (mean (SD))	2.23 (13.57)	449
Vitamin B2, Riboflavin (mg) (mean (SD))	1.73 (2.11)	449
Vitamin B6 (mg) (mean (SD))	2.24 (5.37)	449
Vitamin B12 (µg) (mean (SD))	2.06 (1.43)	446
Folic acid (µg) (mean (SD))	326.82 (161.14)	447
Dietary folate equivalents (µg) (mean (SD))	653.65 (322.28)	447
Niacin (mg) (mean (SD))	16.22 (10.20)	447
Pantothenic acid (mg) (mean (SD))	6.20 (4.64)	447
Biotin (µg) (mean (SD))	17.75 (36.49)	142
Vitamin C (mg) (mean (SD))	92.96 (73.19)	462
Vitamin D (µg) (mean (SD))	10.50 (7.20)	459
Vitamin E (mg) (mean (SD))	11.57 (14.91)	448
Vitamin K (µg) (mean (SD))	48.93 (47.54)	277
Minerals	-	-
Calcium (mg) (mean (SD))	210.48 (320.68)	208
Phosphorus (mean (SD))	2.94 (63.13)	2
Magnesium (mg) (mean (SD))	97.93 (102.28)	420
Iron (mg) (mean (SD))	55.39 (32.18)	470
Zinc (mg) (mean (SD))	7.84 (4.40)	446
Copper (mg) (mean (SD))	0.96 (0.48)	444
Iodine (µg) (mean (SD))	144.43 (70.80)	429
Manganese (mg) (mean (SD))	1.82 (0.89)	445
Chromium (µg) (mean (SD))	29.73 (17.09)	446
Selenium (µg) (mean (SD))	48.55 (22.60)	446
Molybdenum (mcg) (mean (SD))	22.93 (33.29)	188
Fatty Acids	-	-
n3-long chain polyunsaturated fatty acids (mg) (mean (SD))	48.50 (376.96)	29
n6-long chain polyunsaturated fatty acids (mg) (mean (SD))	0.46 (9.98)	2
n9-long chain polyunsaturated fatty acids (mg) (mean (SD))	0.50 (10.87)	2
Fish oil (mg) (mean (SD))	83.74 (601.47)	31
EPA (mg) (mean (SD))	25.34 (189.57)	34
DHA (mg)(mean (SD))	17.80 (125.25)	34

Supplementary Table S4. Daily estimated intake of prenatal supplements assessed at 24 weeks gestation, with 1 month recall, including vitamins, minerals, and fatty acids, with mean (SD) values and number of participants taking each supplement.

	Model 1 n3-LCPUFA	Model 2 D vitamin	Model 3 Prenatal Supplements	Model 4 Energy	Model 5 Maternal ADHD genetic risk	Model 6 Genomic PCs
Neurodevelopmental Diagnosis	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value
All Neurodevelopmental Disorder Diagnosis	1.53 [1.17 - 2.01] (p = 0.002)	1.51 [1.15 - 1.98] (p = 0.003)	1.56 [1.19 - 2.05] (p = 0.001)	1.59 [1.2 - 2.12] (p = 0.001)	1.51 [1.15 - 1.98] (p = 0.003)	1.54 [1.18 - 2.02] (p = 0.002)
ADHD Diagnosis	1.65 [1.21 - 2.26] (p = 0.002)	1.63 [1.19 - 2.24] (p = 0.002)	1.67 [1.22 - 2.29] (p = 0.002)	1.73 [1.25 - 2.44] (p = 0.001)	1.63 [1.19 - 2.24] (p = 0.003)	1.69 [1.23 - 2.35] (p = 0.001)
Autism Diagnosis	2.18 [1.32 - 3.66] (p = 0.002)	2.25 [1.34 - 3.82] (p = 0.002)	2.29 [1.35 - 3.97] (p = 0.002)	2.17 [1.22 - 3.95] (p = 0.009)	2.26 [1.34 - 3.81] (p = 0.002)	2.31 [1.34 - 4.05] (p = 0.003)
Neurodevelopmental Symptom Loads	Estimate [95% CI] p-value	Estimate [95% CI] p-value	Estimate [95% CI] p-value	Estimate [95% CI] p-value	Estimate [95% CI] p-value	Estimate [95% CI] p-value
ADHD Symptom Load (ADHD-RS)	1.76 [1.01 - 2.52] (p < 0.001)	1.73 [0.98 - 2.49] (p < 0.001)	1.78 [1.01 - 2.54] (p < 0.001)	1.76 [0.99 - 2.52] (p < 0.001)	1.68 [0.93 - 2.44] (p < 0.001)	1.78 [1.03 - 2.53] (p < 0.001)
Autism Symptom Load (SRS-2)	3.31 [1.79 - 4.84] (p < 0.001)	3.2 [1.68 - 4.73] (p < 0.001)	3.26 [1.72 - 4.81] (p < 0.001)	3.28 [1.73 - 4.83] (p < 0.001)	3.14 [1.61 - 4.67] (p < 0.001)	3.26 [1.74 - 4.78] (p < 0.001)

Supplementary Table S5. Subanalysis with extra adjustments for the pregnancy Western dietary patterns effect on neurodevelopmental outcomes (multivariable models). **Model 1:** Adjusted for prenatal RCT n-3 LCPUFA. **Model 2:** Adjusted for prenatal RCT high-dose Vitamin D. **Model 3:** Adjusted for prenatal supplements of vitamins, minerals and fatty acids (P1-PC6). **Model 4:** Adjusted for food frequency derived estimated energy intake. **Model 5:** Adjusted for maternal ADHD genetic polygenic risk score **Model 6:** Adjusted for Genomic Principal Components.

	Male Children	Female Children	Interaction
Neurodevelopmental Diagnosis	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value	Estimate [95% CI] p-value
All Neurodevelopmental Disorder Diagnosis	1.42 [1.02 - 1.99] (p = 0.039)	1.86 [1.15 - 3.07] (p = 0.012)	0.75 [0.44 - 1.26] (p = 0.271)
ADHD Diagnosis	1.45 [0.99 - 2.12] (p = 0.052)	2.48 [1.33 - 4.9] (p = 0.005)	0.6 [0.31 - 1.13] (p = 0.120)
Autism Diagnosis	1.83 [0.96 - 3.32] (p = 0.049)	4.28 [1.09 - 26.98] (p = 0.059)	0.5 [0.13 - 1.52] (p = 0.247)
Parental Questionnaires	Estimate [95% CI] p-value	Estimate [95% CI] p-value	Estimate [95% CI] p-value
ADHD Symptom Load (ADHD-RS)	1.87 [0.72 - 3.02] (p = 0.002)	1.32 [0.4 - 2.25] (p = 0.005)	0.66 [-0.73 - 2.06] (p = 0.353)
Autism Symptom Load (SRS-2)	3.15 [1 - 5.31] (p = 0.004)	2.65 [0.51 - 4.79] (p = 0.016)	0.14 [-2.71 - 2.98] (p = 0.926)

Supplementary Table S6. Sex stratification and statistical interaction effect of the pregnancy Western dietary pattern effect on neurodevelopmental outcomes (multivariable models).

ADHD Diagnosis Subtypes	n=	Odds Ratio [95% CI] p-value	n=	Odds Ratio [95% CI] p-value
ADHD combined presentation (DSM-5)	30/508	1.51 [1.03 - 2.20] (p = 0.033)	-	-
ADHD predominantly inattentive presentation (DSM-5)	25/508	1.71 [1.13 - 2.56] (p = 0.009)	-	-
Neurodevelopmental Symptom Loads	n=	Whole Cohort [95% CI] p-value	n=	Excluding Neurodevelopmental Disorder Diagnosis [95% CI] p-value
ADHD-RS Inattention Score	513	0.98 [0.52 - 1.45] (p < 0.001)	428	0.31 [-0.08 - 0.7] (p = 0.124)
ADHD-RS Hyperactivity and Impulsivity Score	509	0.74 [0.38 - 1.11] (p < 0.001)	425	0.34 [0.01 - 0.67] (p = 0.043)
ADHD-RS Total (ADHD Symptom Load)	509	1.73 [0.98 - 2.49] (p < 0.001)	425	0.63 [0.01 - 1.25] (p = 0.048)
SRS-2 Restricted interests and repetitive behaviour Score	513	0.6 [0.26 - 0.94] (p < 0.001)	428	0.15 [-0.13 - 0.44] (p = 0.296)
SRS-2 Social communication and interaction Score	513	2.61 [1.35 - 3.87] (p < 0.001)	428	0.88 [-0.29 - 2.05] (p = 0.143)
SRS-2 Total (Autism Symptom Load)	513	3.21 [1.69 - 4.74] (p < 0.001)	428	1.03 [-0.34 - 2.4] (p = 0.141)

Supplementary Table S7. The pregnancy Western dietary patterns effect on ADHD diagnosis subtypes, and subscores of ADHD and autism symptoms loads (multivariable models). **Column 1:** The entire COPSAC2010 **Column 2:** Subanalysis with any neurodevelopmental disorder diagnosis excluded.

Neurodevelopmental Diagnosis		Univariate Model	Multivariable Model
PC2 Trained in COPSAC2010	n=	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value
Any Neurodevelopmental Disorder Diagnosis	4069/59725 (6.8%)	1.10 [1.07 - 1.14], p<0.0001)	1.03 [1.00 - 1.07], p = 0.087
ADHD Diagnosis	2764/59725 (4.6%)	1.16 [1.11 - 1.20], p<0.0001	1.07 [1.02 - 1.11], p = 0.002
Autism Diagnosis	1639/59725 (2.7%)	1.06 [1.00-1.11], p=0.030	1.04 [0.98-1.09], p=0.351
PC2 Trained in DNBC	n=	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value
Any Neurodevelopmental Disorder Diagnosis	4069/59725 (6.8%)	1.10 [1.06 - 1.14], p<0.0001)	1.03 [1.00 - 1.07], p = 0.054
ADHD Diagnosis	2764/59725 (4.6%)	1.13 [1.09 - 1.18], p<0.0001	1.05 [1.01 - 1.10], p = 0.018
Autism Diagnosis	1639/59725 (2.7%)	1.06 [1.00-1.11], p=0.020	1.04 [0.99-1.10], p=0.130

Supplementary Table S8. External validation of the association between the pregnancy Western dietary pattern (PC2), trained within COPSAC2010, and within the DNBC and registry derived neurodevelopmental diagnosis in the DNBC cohort.

BIOCHEMICAL	SUPER PATHWAY	SUB PATHWAY	Comp.1 (x 10 ⁻³)	Mediating Metabolite
ergothioneine	Xenobiotics	Food Component/Plant	-3.737	Yes
carotene diol (1)	Cofactors and Vitamins	Vitamin A Metabolism	-3.125	Yes
branched chain 14:0 dicarboxylic acid	Lipid	Fatty Acid, Dicarboxylate	-2.759	Yes
indolepropionate	Amino Acid	Tryptophan Metabolism	-2.533	Yes
1-palmitoyl-2-docosahexaenoyl-G PC (16:0/22:6)	Lipid	Phosphatidylcholine (PC)	-2.517	Yes
sphingomyelin (d18:2/18:1)*	Lipid	Sphingomyelins	2.226	Yes
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4)	Lipid	Phosphatidylethanolamine (PE)	2.190	Yes
caprate (10:0)	Lipid	Medium Chain Fatty Acid	2.164	Yes
tartarate	Xenobiotics	Food Component/Plant	-2.155	Yes
3-hydroxystachydrine*	Xenobiotics	Food Component/Plant	-2.054	Yes
caprylate (8:0)	Lipid	Medium Chain Fatty Acid	1.985	Yes
branched-chain, straight-chain, or cyclopropyl 10:1 fatty acid (1)*	Partially Characterized Molecules	Partially Characterized Molecules	1.948	Yes
1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1)	Lipid	Plasmalogen	1.900	Yes
pregnen-diol disulfate*	Lipid	Pregnenolone Steroids	1.895	Yes
threonate	Cofactors and Vitamins	Ascorbate and Aldarate Metabolism	-1.885	Yes
hydroxy-CMPF*	Lipid	Fatty Acid, Dicarboxylate	-3.485	No
beta-cryptoxanthin	Cofactors and Vitamins	Vitamin A Metabolism	-3.482	No
3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF)	Lipid	Fatty Acid, Dicarboxylate	-3.032	No
2,6-dihydroxybenzoic acid	Xenobiotics	Drug - Topical Agents	-2.912	No
carotene diol (2)	Cofactors and Vitamins	Vitamin A Metabolism	-2.566	No
1-oleoyl-GPG (18:1)*	Lipid	Lysophospholipid	2.494	No
1-stearoyl-2-docosahexaenoyl-GP C (18:0/22:6)	Lipid	Phosphatidylcholine (PC)	-2.443	No
pentose acid*	Partially Characterized Molecules	Partially Characterized Molecules	-2.413	No

2-aminophenol sulfate	Xenobiotics	Chemical	-2.377	No
1-arachidonoyl-GPE (20:4n6)*	Lipid	Lysophospholipid	2.363	No
eicosapentaenoylcholine	Lipid	Fatty Acid Metabolism (Acyl Choline)	-2.338	No
ethyl beta-glucopyranoside	Xenobiotics	Food Component/Plant	-2.267	No
2-hydroxyarachidate*	Lipid	Fatty Acid, Monohydroxy	2.263	No
hippurate	Xenobiotics	Benzoate Metabolism	-2.249	No
3-phenylpropionate (hydrocinnamate)	Xenobiotics	Benzoate Metabolism	-2.248	No
1-oleoyl-GPE (18:1)	Lipid	Lysophospholipid	2.147	No
tartronate (hydroxymalonate)	Xenobiotics	Food Component/Plant	-2.108	No
gamma-CEHC	Cofactors and Vitamins	Tocopherol Metabolism	2.052	No
pregnenetriol disulfate*	Lipid	Pregnenolone Steroids	2.006	No
stachydrine	Xenobiotics	Food Component/Plant	-1.994	No
pyridoxate	Cofactors and Vitamins	Vitamin B6 Metabolism	-1.944	No
1-stearoyl-2-oleoyl-GPC (18:0/18:1)	Lipid	Phosphatidylcholine (PC)	1.943	No
eicosanedioate (C20-DC)	Lipid	Fatty Acid, Dicarboxylate	1.931	No
sphingosine	Lipid	Sphingosines	1.926	No
1-stearoyl-2-arachidonoyl-GPC (18:0/20:4)	Lipid	Phosphatidylcholine (PC)	1.897	No
androstenediol (3beta,17beta) disulfate (1)	Lipid	Androgenic Steroids	1.884	No
cysteine s-sulfate	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism	1.879	No
1-linolenoyl-GPC (18:3)*	Lipid	Lysophospholipid	1.876	No

Supplementary Table S9. The 43 metabolites surviving regularisation in the pregnancy Western dietary patterns sparse partial least squares model in COPSAC2010. Metabolites name, super pathway, sub pathways, loadings for component 1 and whether or not the metabolite significantly mediated the association between the Western dietary pattern and any Neurodevelopmental Disorder Diagnosis.

COPSAC2010 Western Dietary Pattern Metabolite Score Correlation Matrix	Maternal - 24 Weeks Gestation	Maternal - 1 week Postpartum	Child - 6 months	Child - 18 months	Child - 6 years
Maternal - 24 Weeks Gestation	1	0,68	0,42	0,46	0,33
Maternal - 1 week Postpartum	0,68	1	0,38	0,40	0,27
Child - 6 months	0,42	0,38	1	0,3	0,21
Child - 18 months	0,46	0,40	0,30	1	0,39
Child - 6 years	0,33	0,27	0,21	0,39	1
VDAART Western Dietary Pattern Metabolite Score Correlation Matrix	Maternal - 10-18 weeks Gestation	Maternal - 32-38 weeks gestation	Child - 1 year	Child - 3 years	Child - 6 years
Maternal - 10-18 weeks Gestation	1	0,72	0,48	0,35	0,40
Maternal - 32-38 weeks gestation	0,72	1	0,50	0,34	0,41
Child - 1 year	0,48	0,50	1	0,64	0,54
Child - 3 years	0,35	0,34	0,64	1	0,62
Child - 6 years	0,40	0,41	0,54	0,62	1

Supplementary Table S10. Correlation matrices of the respective maternal and child Western dietary pattern Metabolite Scores in the COPSAC2010 and VDAART cohorts.

Cohort Characteristics	COPSAC2010	VDAART	p-value	COPSAC2000	p-value
n =	600	656		348	
Age (years) (mean (SD))	10.3 (0.3)	6.0 (0.1)	<0.001	17.7 (0.6)	<0.001
Male Sex (%)	310 (51.7)	341 (52.1)	0.934	172 (49.4)	0.55
Caucasian Race (%)	573 (95.5)	254 (40.3)	<0.001	339 (97.4)	0.19
Income type (%)			<0.001		<0.001
Low	48 (13.0)	81 (34.9)		90 (26.9)	
Medium	114 (31.0)	78 (33.6)		216 (64.5)	
High	206 (56.0)	73 (31.5)		29 (8.7)	
Maternal Education Attainment at Birth			<0.001		<0.001
Low	46 (7.7)	232 (36.8)		186 (55.9)	
Medium	373 (62.2)	170 (26.9)		94 (28.2)	
High	181 (30.2)	229 (36.3)		53 (15.9)	
Maternal age at birth (years) (mean (SD))	32.4 (4.3)	25.49 (5.42)	<0.001	30.1 (4.6)	<0.001
Maternal Pre-pregnancy Body Mass Index (mean(SD))	24.6 (4.4)	28.5 (7.9)	<0.001	-	-
Birthweight (kilograms) (mean (SD))	3.5 (0.5)	3.3 (0.6)	<0.001	3.5 (0.5)	0.655
Gestational age (days) (mean (SD))	279 (12)	273 (14)	<0.001	282 (11)	<0.001
Caesarean section (%)	125 (20.8)	187 (29.7)	<0.001	74 (21.3)	0.941
Maternal smoking during pregnancy (%)	44 (7.3)	18 (2.8)	<0.001	79 (22.7)	<0.001
ADHD Diagnosis (%) / 6 years (VDAART)	65 (11.0)	18 (2.7)	<0.001	-	-
ADHD Diagnosis (%) / Ever 8 years (VDAART)	65 (11.0)	57 (8.7)	0.213	-	-
ADHD-RS total score (mean(SD))	9.9 (8.7)	-	-	-	-
ASRS total score (mean(SD))	-	-	-	4.1 (3.9)	-

Supplementary Table S11. Cohort characteristics stratified by cohorts. P-values summarise cohort characteristic differences between COPSAC2010/VDAART and COPSAC2010/COPSAC2000 respectively. Low, medium, and high income are defined as <50,000, 50,000 - 110,000, and >110,000 Euro in COPSAC2010/COPSAC2000, and <30,000, 30,000 - 99,999, and >\$100,000 USD in VDAART, respectively. Low, medium and high level educational attainment are defined as “primary, secondary, or college graduate”, “tradesman or bachelor’s degree” and “Masters degree” in COPSAC2010/COPSAC2000 and “Did not graduate from high school/Graduated from high school”, “Technical school/Junior college/some college” and “Graduate school/College graduate” in VDAART.

	Maternal Pre-pregnancy BMI	Child Sex (Male)	Child ADHD Polygenic Risk Score	Child Autism Polygenic Risk Score
Neurodevelopmental Diagnosis	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value	Odds Ratio [95% CI] p-value
All Neurodevelopmental Disorder Diagnosis	1.04 [0.99 - 1.10] (p = 0.097)	2.74 [1.66 - 4.65] (p < 0.001)	1.50 [1.16 - 1.94] (p = 0.002)	1.30 [1.02 - 1.67] (p = 0.039)
ADHD Diagnosis	1.05 [0.99 - 1.11] (p = 0.102)	3.54 [1.94 - 6.79] (p < 0.001)	1.60 [1.19 - 2.18] (p = 0.002)	1.47 [1.10 - 1.97] (p = 0.009)
Autism Diagnosis	1.13 [1.03 - 1.24] (p = 0.006)	1.90 [0.65 - 6.06] (p = 0.250)	1.45 [0.83 - 2.56] (p = 0.197)	1.44 [0.83 - 2.54] (p = 0.196)
Neurodevelopmental Symptom Loads	Estimate [95% CI] p-value	Estimate [95% CI] p-value	Estimate [95% CI] p-value	Estimate [95% CI] p-value
ADHD Symptom Load (ADHD-RS)	0.24 [0.08 - 0.39] (p = 0.003)	4.04 [2.73 - 5.35] (p < 0.001)	1.37 [0.68 - 2.05] (p < 0.001)	1.20 [0.52 - 1.87] (p < 0.001)
Autism Symptom Load (SRS-2)	0.46 [0.15 - 0.78] (p = 0.004)	3.98 [1.31 - 6.65] (p = 0.004)	1.60 [0.19 - 3.00] (p = 0.026)	1.78 [0.40 - 3.16] (p = 0.012)

Supplementary Table S12. Maternal pre-pregnancy BMI and child sex associations on neurodevelopmental outcomes, with the Western dietary pattern included in multivariable models, shows the independent associations of maternal pre-pregnancy BMI and child sex on neurodevelopmental diagnosis and symptom loads. Furthermore, models show the associations with child ADHD and autism polygenic risk scores (PRS), likewise also adjusted for the Western dietary pattern, on neurodevelopmental diagnosis and symptom loads.

	Missingness all metabolites (#1131)		Missingness selected metabolites (#43)	
Neurodevelopmental Diagnosis	Odds Ratio [95% CI]	p-value	Odds Ratio [95% CI]	p-value
Any Neurodevelopmental disorder	OR = 1.004 [0.998; 1.011]	0.2	OR = 1.097 [0.848; 1.403]	0.468
ADHD	OR = 1 [0.992; 1.008]	0.923	OR = 0.953 [0.698; 1.273]	0.753
Autism	OR = 1.009 [0.994; 1.023]	0.213	OR = 0.961 [0.516; 1.628]	0.89
Neurodevelopmental Symptom Loads	Estimate [95% CI]	p-value	Estimate [95% CI]	p-value
ADHD Symptom Load (ADHD-RS)	B = 0.002 [0; 0.005]	0.084	B = 0.028 [-0.064; 0.12]	0.55
Autism Symptom Load (SRS-2)	B = 0.001 [-0.001; 0.004]	0.356	B = 0.013 [-0.078; 0.105]	0.772
Exposure	Estimate [95% CI]	p-value	Estimate [95% CI]	p-value
Western Dietary Pattern	B = 0 [-0.003; 0.002]	0.904	B = 0.106 [0.016; 0.196]	0.021

Supplementary Table S13. Analysis of missing metabolites and their association with neurodevelopmental outcomes. Missingness rates of all metabolites and the selected 43 metabolites in the pregnancy Western dietary pattern metabolite score, alongside their odds ratios and confidence intervals for neurodevelopmental disorders, symptom loads and the Western dietary pattern.